Document:

EX-10.3

 

CONFIDENTIAL
MATERIALS OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION.
ASTERISKS DENOTE OMISSIONS

EXHIBIT 10.3

AMENDED AND RESTATED LICENSE AGREEMENT

          THIS AMENDED AND RESTATED LICENSE AGREEMENT (this “Agreement”) dated as of April 20,
2007 (the “Restatement Date”) between Pfizer Inc., a corporation organized under the laws
of the state of Delaware, with its principal place of business at 235 East 42nd Street, New York,
New York 10017 (“Pfizer”), and (OSI) Eyetech, Inc. (formerly known as Eyetech
Pharmaceuticals, Inc.), a corporation organized under the laws of the state of Delaware, with its
principal place of business at 140 E. Hanover Avenue, Cedar Knolls, New Jersey 07927
(“Eyetech”).

          WHEREAS, on December 17, 2002, Pfizer and Eyetech entered into a License Agreement (as amended
prior to the Restatement Date, the “Original License Agreement”), whereby, inter
alia, Eyetech granted to Pfizer an exclusive license or sublicense to certain patents and
patent applications, know-how, trade secrets and scientific and technical information relating to
Macugen® throughout the world, and a Collaboration Agreement (the “Collaboration
Agreement”), in which Eyetech and Pfizer agreed, inter alia, to co-promote Macugen® in
the US Territory (as defined below);

          WHEREAS, the Parties no longer desire to co-promote Macugen® in the US Territory; and

          WHEREAS, Pfizer desires to continue to develop and commercialize the Product (as defined
below) in the ROW Territory (as defined below).

          NOW, THEREFORE, the Parties agree to terminate the Collaboration Agreement and amend and
restate the Original License Agreement in its entirety as follows:

ARTICLE 1

DEFINITIONS

          1.1 “AAA” has the meaning set forth in Section 14.1(a).

1

 

          1.2 “Affiliate” means any Person directly or indirectly controlled by, controlling or
under common control with, a Party, but only for so long as such control shall continue. For
purposes of this definition, “control” (including, with correlative meanings, “controlled by”,
“controlling” and “under common control with”) means, with respect to a Person, possession, direct
or indirect, of (a) the power to direct or cause direction of the management and policies of such
Person (whether through ownership of securities or partnership or other ownership interests, by
contract or otherwise), or (b) at least 50% of the voting securities (whether directly or pursuant
to any option, warrant or other similar arrangement) or other comparable equity interests. For the
avoidance of doubt, neither of the Parties shall be deemed to be an “Affiliate” of the other.

          1.3 “Bankruptcy Code” means 11 U.S.C §§ 101-1330, as amended.

          1.4 “Amended and Restated Distribution Agreement” means the Amended and Restated
Distribution Agreement between Eyetech and Pfizer dated as of the date hereof.

          1.5 “Amended and Restated Regulatory Services Agreement” means the Amended and
Restated Regulatory Services Agreement between Eyetech and Pfizer dated as of the date hereof.

          1.6 “Assignment and Assumption Agreement for Manufacturing Agreements” means the
Assignment and Assumption Agreement between Eyetech and Pfizer, dated as of the date hereof,
pursuant to which the agreements set forth on Schedule 4.9(b) are assigned from Eyetech to
Pfizer.

          1.7 “Assignment and Assumption Agreement for US Territory Agreements” means the
Assignment and Assumption Agreement among Eyetech, Pfizer and OSI Pharmaceuticals, Inc. (“OSIP”),
dated as of the date hereof, pursuant to which the US Territory Agreements are assigned from Pfizer
and/or OSIP to Eyetech.

          1.8 “Bill of Sale” means the bill of sale in the form attached hereto as Exhibit
1.8.

2

 

          1.9 “Bulk Drug Substance Supplier” means a third-party supplier of bulk drug substance
for the Product with which Pfizer has entered into a supply agreement.

          1.10 “Business Day” means a day other than a Saturday, Sunday, or bank or other public
holiday in New York, New York.

          1.11 “Collaboration Agreement” has the meaning set forth in the Recitals to this
Agreement.

          1.12 “Compound” means the anti-VEGF aptamer that is the active pharmaceutical
ingredient in Macugen® as of the Restatement Date, and is more specifically described in
Schedule 1.12.

          1.13 “Confidential Information” means all trade secrets or other proprietary
information, including without limitation any proprietary data and materials (whether or not
patentable or protectable as a trade secret), regarding a Party’s technology, products, business or
objectives or regarding the Product, which is disclosed by a Party to the other Party.
Notwithstanding the foregoing, there shall be excluded from the foregoing definition of
Confidential Information any of the foregoing that:

                    (a) was known by the receiving Party or an Affiliate prior to its date of disclosure to the
receiving Party as shown by the receiving Party’s or its Affiliate’s written records; or

                    (b) either before or after the date of the disclosure to the receiving Party is lawfully
disclosed to the receiving Party or its Affiliate by third parties not in violation of any
obligation to the other Party; or

3

 

                    (c) either before or after the date of the disclosure to the receiving Party becomes published
or generally known to the public through no fault or omission on the part of the receiving Party or
its Affiliates; or

                    (d) is independently developed by or for the receiving Party or its Affiliate without
reference to or reliance upon the Confidential Information as demonstrated by contemporaneous
written records of the receiving Party or its Affiliate; or

                    (e) is required to be disclosed by the receiving Party or its Affiliate to comply with
applicable Laws, to defend or prosecute litigation or to comply with governmental regulations or
the regulations or requirements of any stock exchange, including Nasdaq, provided
that the receiving Party provides prior notice of such disclosure to the other Party and
takes reasonable and lawful actions to avoid and/or minimize the degree of such disclosure.

          1.14 “Control” or “Controlled” means, with respect to any intellectual
property right, the possession (whether by ownership or license) by a Party (or by any Affiliate of
a Party) of the ability to grant to the other Party a license under such right without violating
the terms of any agreement with a third party.

          1.15 “Courts” has the meaning set forth in Section 15.4.

          1.16 “Current Inventories” has the meaning set forth in Section 4.9(c).

          1.17 “DDMAC” means the FDA’s Division of Drug Marketing Advertising and
Communications, or its equivalent in the ROW Territory.

          1.18 “Degussa Agreement” means the Manufacturing and Supply Agreement dated as of
November 11, 2003, by and between Degussa Canada Inc. (as successor in interest to Raylo Chemicals
Inc.) and Eyetech, assigned to Pfizer pursuant to the Assignment and Assumption Agreement for
Manufacturing Agreements.

4

 

          1.19 “Eyetech Capital Equipment” has the meaning set forth in Section 4.9(f).

          1.20 “Eyetech Parties” has the meaning set forth in Section 11.2.

          1.21 “Eyetech Patent Rights” means all Patent Rights Controlled by Eyetech or its
Affiliates as of the Restatement Date relating to, or useful in connection with, the manufacture,
use or sale of the Compound or the Product in the ROW Territory, including the patents and patent
applications set forth on Schedule 1.21. Any patentable inventions that have been reduced
to practice prior to the Restatement Date for which a patent application is not filed until after
the Restatement Date shall be included within the definition of Eyetech Patent Rights.**

          1.22 “Eyetech Technical Information” means all scientific or technical information and
related know-how and trade secrets, Controlled by Eyetech or its Affiliates as of the Restatement
Date relating to the Compound or the Product, including but not limited to: (a) medical, clinical,
toxicological or other scientific data and (b) processes and analytical methodology useful in the
development, testing, analysis, manufacture or packaging of the Compound or the Product.

          1.23 “Eyetech Third Party Licensors” shall mean (a) Gilead, Nektar and Isis, and (b)
any additional third party licensors that are identified by Eyetech to Pfizer with respect to a New
Product in the course of negotiating an agreement pursuant to Section 3.5 concerning such New
Product.

          1.24 “FDA” means the United States Food and Drug Administration and any successor
agency thereto.

          1.25 “Field” means the prevention, treatment or control of all ophthalmic diseases or
conditions.

 

			
	**	 	This portion has been redacted pursuant to a
confidential treatment request.

5

 

          1.26 “Fill and Finish Services Supplier” means a third party supplier of fill and
finish services necessary to produce the Product in finished (i.e., ready for administration to
patients) form for sale in the ROW Territory with which Pfizer has entered into an agreement.

          1.27 “Gilead License” means the Licensing Agreement dated as of March 30, 2000, by and
among Eyetech, Gilead Sciences, Inc. (“Gilead”) and NeXstar Pharmaceuticals, Inc., as
amended from time to time.

          1.28 “Global Congresses” has the meaning set forth in Section 4.4(g)(ii).

          1.29 “Governmental Authority” means any court, agency, department or other
instrumentality of any foreign, federal, state, county, city or other political subdivision.

          1.30 “Isis License” means the License Agreement dated as of December 31, 2001, by and
between Eyetech and Isis Pharmaceuticals, Inc. (“Isis”), as amended from time to time.

          1.31 “Joint Inventions” shall have the meaning set forth in Section 9.12.

          1.32 “Joint Patent Rights” means Patent Rights that claim Joint Inventions.

          1.33 “Law” or “Laws” means all laws, statutes, rules, codes, regulations,
orders, judgments and/or ordinances of any Governmental Authority.

          1.34 “Losses” means, subject to Section 10.4, any and all (a) claims, losses,
liabilities, damages, fines, royalties, governmental penalties or punitive damages, deficiencies,
interest, awards, and judgments, (b) with respect to third parties, settlement amounts and all of
the items referred to in clause (a) above which, in accordance with Section 10.4, include third
party special, indirect, incidental, consequential damages (including without limitation lost
profits) and third party punitive and multiple damages, and (c) in connection with all of the items
referred in clauses (a) and (b) above, any and all costs and expenses (including reasonable
attorneys’ fees and all other

6

 

expenses reasonably incurred in investigating, preparing or defending any litigation or
proceeding, commenced or threatened).

          1.35 “Nektar License” means the License, Manufacturing and Supply Agreement dated as
of February 5, 2002, by and between Eyetech and Nektar Therapeutics (formerly Shearwater
Corporation) (“Nektar”), as amended as of January 23, 2006.

          1.36 “Net Sales” means the gross amounts billed or invoiced by Pfizer, its Affiliates
and sublicensees for the Product in the ROW Territory, less the following deductions:

                    (a) trade, quantity and cash discounts allowed, but expressly excluding discounts or
allowances offered as part of a package of products that includes a Product sold by Pfizer, its
Affiliates or sublicensees;

                    (b) refunds, chargebacks and any other allowances which effectively reduce the net selling
price;

                    (c) actual product returns, credits and allowances allowed to customers, and actual bad debts;

                    (d) rebates actually paid or credited to any governmental agency (or branch thereof) or to any
third party payor, administrator or contractee;

                    (e) discounts mandated by, or granted to meet the requirements of, applicable state,
provincial or federal law, wholesaler, including required chargebacks and retroactive price
reductions;

                    (f) transportation, freight, postage charges and other charges, such as insurance, relating
thereto, in each case included as a specific line item on an invoice to such third parties; and

7

 

                    (g) taxes, excises or other governmental charges upon or measured by the production, sale,
transportation, delivery or use of goods, in each case included as a specific line item on an
invoice to such third parties.

          If any such sales to third parties are made in transactions that are not at arm’s length
between the buyer and the seller, then the gross amount to be included in the calculation of Net
Sales shall be the amount that would have been invoiced had the transaction been conducted at arm’s
length. Such amount that would have been invoiced shall be determined, wherever possible, by
reference to the average selling price of the Product in arm’s-length transactions in the relevant
country.

          If Pfizer, its Affiliate or sublicensee sells a Product in unfinished form to a third party
for resale, then the gross amount to be included in the calculation of Net Sales arising from such
sale shall be the amount invoiced by the third party upon resale, in lieu of the amounts invoiced
by Pfizer, its Affiliates or sublicensee when selling the Product in unfinished form. Otherwise,
where Pfizer, its Affiliate or sublicensee sells a Product in finished form to a third party that
does not require a sublicense under the Eyetech Patent Rights for further resale (each such third
party hereinafter a “Distributor”), the amount to be included in the calculation of Net
Sales shall be the price invoiced from Pfizer or its Affiliate or sublicensee to the third party,
not the amount invoiced by the third party upon resale.

          If, in addition to or in lieu of a transfer price paid for quantities of Product supplied, any
Distributor provides consideration to Pfizer, its Affiliate or sublicensee in connection with any
Product or the Distributor’s rights or relationship with Pfizer, its Affiliate or sublicensee in
relation thereto, then such consideration shall be included in the calculation of Net Sales in the
Pfizer Quarter in which it becomes due to Pfizer or its Affiliate or sublicensee (as applicable).

8

 

Notwithstanding the foregoing, amounts received by Pfizer, or its Affiliates or sublicensees,
for the sale of the Product among Pfizer and its Affiliates or sublicensees for resale shall not be
included in the computation of Net Sales hereunder.

          Net Sales shall be determined from books and records maintained in accordance with GAAP,
consistently applied throughout the organization and across all products of the entity whose sales
of Product are giving rise to Net Sales.

          1.37 “New Product” means, other than the prescription pharmaceutical product
containing the Compound and known as Macugen® as of the Restatement Date and any new doses and
dosing regimens thereof approved after the Restatement Date, provided that such new doses or dosing
regimens do not alter the Product itself or any ingredient contained in such Product as of the
Restatement Date, any product that (a) contains or is based on the Compound, or any metabolites or
prodrugs of such aptamer or any hydrates, conjugates, salts, esters, isomers, polymorphs or
analogues of any of the foregoing, either alone or in combination with one or more other
therapeutically active substances, and (b) is for use in the Field; including for the avoidance of
doubt any un-pegylated formulation of the prescription pharmaceutical product containing the
Compound and known as Macugen® as of the Restatement Date.

          1.38 “Ongoing Trials” has the meaning set forth in Section 4.2.

          1.39 “Ongoing Trial Data” means all results and data arising from the Ongoing Trials,
including without limitation all raw data and final results.

          1.40 “Original License Agreement” shall have the meaning set forth in the Recitals to
this Agreement.

          1.41 “Other Components” shall have the meaning set forth in Section 4.9(c).

9

 

          1.42 “Out-of-Pocket Costs” means costs and expenses paid to third parties (or payable
to third parties and accrued in accordance with GAAP), other than Affiliates or employees, by
either Party after the Restatement Date.

          1.43 “Packaging Materials” has the meaning set forth in Section 9.7.

          1.44 “Party” means either Eyetech or Pfizer; “Parties” means both Eyetech and
Pfizer.

          1.45 “Patent Rights” means the rights and interest in and to all issued patents and
pending patent applications in any country in the Territory, including all divisionals,
continuations, renewals, continuations-in-part, patents of addition, supplementary protection
certificates, extensions, registrations or confirmation patents and reissues thereof.

          1.46 “Person” means any natural person or any corporation, company, partnership, joint
venture, firm or other entity, including without limitation a Party.

          1.47 “Pfizer Capital Equipment” has the meaning set forth in Section 4.9(g).

          1.48 “Pfizer Parties” has the meaning set forth in Section 11.1.

          1.49 “Pfizer Patent Rights” means all Patent Rights Controlled by Pfizer or its
Affiliates as of the Restatement Date, relating to, or useful in connection with, the manufacture,
use or sale of the Compound or the Product in the US Territory. Any patentable inventions that
have been reduced to practice prior to the Restatement Date for which a patent application is not
filed until after the Restatement Date shall be included in Pfizer Patent Rights.

          1.50 “Pfizer Quarter” means each of the four (4) thirteen (13) week periods, the first
commencing on December 1 of any Year.

          1.51 “Pfizer Technical Information” means all scientific or technical information and
related know-how and trade secrets, Controlled by Pfizer or its Affiliates as of the Restatement
Date, including but not limited to: (a) medical, clinical, toxicological or other scientific data
and (b)

10

 

processes and analytical methodology useful in the development, testing, analysis, manufacture
or packaging of the Compound or the Product.

          1.52 “Pharmacovigilance Agreement” has the meaning set forth in Section 4.5.

          1.53 “Prior Agreements” means the following agreements entered into between Pfizer and
Eyetech: the Collaboration Agreement, the Detailing Services Agreement dated December 17, 2002,
and the Mutual Consent Establishing the Technology Subcommittee dated February 4, 2004.

          1.54 “Product” means (a) the prescription pharmaceutical product containing the
Compound and known as Macugen® as of the Restatement Date, for any use in the Field, and (b) any
New Product with respect to which the license granted to Pfizer in Section 3.1 is expanded pursuant
to Section 3.5. For the avoidance of doubt, Product shall include new doses and dosing regimens
thereof approved after the Restatement Date, provided that such new doses or dosing regimens do not
alter the Product itself or any ingredient contained in such Product as of the Restatement Date.

          1.55 “Product Components” has the meaning set forth in Section 4.9(a).

          1.56 “Quarterly Expense Reports” has the meaning set forth in Section 5.2(a).

          1.57 “Regulatory Authority” means any federal, national, multinational, state,
provision, or local regulatory agency, department, bureau or other governmental entity with
authority over the testing, manufacture, use, storage, import, promotion, marketing and sale of a
pharmaceutical product in a country, including the FDA.

          1.58 “Required Consents” has the meaning set forth in Section 4.9(b).

          1.59 “Responsible Party” has the meaning set forth in Section 4.2.

          1.60 “Restatement Date” has the meaning set forth in the opening paragraph of this
Agreement.

11

 

          1.61 “ROW Territory” means all countries in the world outside the US Territory.

          1.62 “Technical Information” means Eyetech Technical Information or Pfizer Technical
Information.

          1.63 “Territory” means the US Territory and/or the ROW Territory, as the case may be.

          1.64 “Third Party Claims” has the meaning set forth in Section 11.1(a)(ii).

          1.65 “Trademarks” means (a) the registered and unregistered trademarks and trade names
in use as of the Restatement Date related to the Product including those marks reflected on
Exhibit 1.65; and (b) any aspect of Product packaging in use as of the Restatement Date
that constitutes protectable trade dress; but in each case excluding the Eyetech name and logo.

          1.66 “Transaction Agreements” mean this Agreement, the Amended and Restated Regulatory
Services Agreement, the Amended and Restated Distribution Agreement, the Assignment and Assumption
Agreement for Manufacturing Agreements, the Assignment and Assumption Agreement for US Territory
Agreements, the Bill of Sale, the Pharmacovigilance Agreement and the Transitional Services
Agreement.

          1.67 “Transitional Services Agreement” means the transitional services agreement
between the Parties entered into on the Restatement Date pursuant to which Eyetech has agreed to
provide to Pfizer certain services, including supply, analytical, stability and clinical trial
support services, with respect to the Product and Product Components.

          1.68 “US Territory” means United States of America, its territories, possessions and
Puerto Rico.

          1.69 “US Territory Agreements” has the meaning set forth in Section 4.4(e).

          1.70 “Year” means a calendar year.

          1.71 Other Definitional Provisions.

12

 

                    (a) The words “hereof”, “herein”, “hereto” and “hereunder” and words of similar import, when
used in this Agreement shall refer to this Agreement as a whole and not to any particular provision
of this Agreement.

                    (b) The terms defined in the singular shall have a comparable meaning when used in the plural,
and vice versa.

                    (c) The term “including” shall mean “including, without limitation”.

ARTICLE 2

AMENDMENT AND RESTATEMENT OF ORIGINAL LICENSE AGREEMENT;

TERMINATION OF PRIOR AGREEMENTS; 

OTHER TRANSACTION AGREEMENTS

          2.1 Original License Agreement. This Agreement amends and restates the Original
License Agreement in its entirety. Notwithstanding anything to the contrary herein, this Agreement
shall not relieve either Party of any obligations the performance of which were owed under the
Original License Agreement prior to the Restatement Date.

          2.2 Prior Agreements. Effective as of the Restatement Date, the Prior Agreements, and
all rights and obligations of the Parties thereunder, are terminated in their entirety (including,
without limitation, provisions under the Prior Agreements that would otherwise survive such
termination) by mutual consent of the Parties and shall no longer be in effect, except for the
following provisions of the Collaboration Agreement, which shall survive termination of the
Collaboration Agreement as set forth below: (a) each Party’s obligations with respect to expenses
and Net Sales which have accrued under the Collaboration Agreement prior to the Restatement Date
and which shall be reconciled pursuant to Section 5.1 of this Agreement, and (b) the obligations of
the Parties with respect to accounts and reports (Article 9 of the Collaboration Agreement),
ownership of intellectual property (Article 10 of the Collaboration Agreement), the protection and
nondisclosure of Confidential Information (Article 11 of the Collaboration

13

 

Agreement), dispute resolution (Article 15 of the Collaboration Agreement) and indemnification
(Sections 12.4, 12.5, 12.6, 12.7, 12.8 and 12.9 of the Collaboration Agreement). For the avoidance
of doubt, Section 14.1 of the Collaboration Agreement (Non-Competition) shall terminate and have no
further force or effect from and after the termination of the Collaboration Agreement.

          2.3 Other Transaction Agreements. Concurrently with the execution of this Agreement,
the Parties are executing the Amended and Restated Distribution Agreement, the Amended and Restated
Regulatory Services Agreement, the Assignment and Assumption Agreement for Manufacturing
Agreements, the Assignment and Assumption Agreement for US Territory Agreements, the Bill of Sale,
and the Transitional Services Agreement. The Pharmacovigilance Agreement shall survive the
execution of this Agreement and the termination of the Prior Agreements in accordance with its
terms.

ARTICLE 3

LICENSES

          3.1 Eyetech Grants.

               (a) Subject to the terms of this Agreement, Eyetech hereby grants to Pfizer, and Pfizer hereby
accepts, (i) an exclusive (even as to Eyetech, subject to a retained right by Eyetech to develop,
use, make, have made and import the Product in the ROW Territory solely for the purpose of
obtaining regulatory approval(s) for the Product in the US Territory and developing and supplying
the Product for sale and importation in the US Territory), royalty-free (except as otherwise set
forth in Article 6) license under the Eyetech Patent Rights, Eyetech Technical Information, and
Eyetech’s rights under any Joint Patent Rights and Ongoing Trial Data, to develop, use, make, have
made, sell, offer for sale, import, and have imported the Product in the ROW Territory, and (ii) a
nonexclusive, royalty-free (except as otherwise set forth in Article 6) license under the Eyetech
Patent Rights and corresponding US Territory Patent Rights owned or

14

 

Controlled by Eyetech or its Affiliates, Eyetech Technical Information, and Eyetech’s rights
under any Joint Patent Rights and Ongoing Trial Data, to develop, use, make, have made and import
the Product in the US Territory solely for the purpose of developing and supplying the Product for
sale and importation in the ROW Territory.

               (b) The licenses granted in Section 3.1(a) include sublicenses, as applicable. The
sublicenses granted by Eyetech to Pfizer in Section 3.1(a) are subject to the following terms of
the Gilead License, the Isis License and the Nektar License, respectively:

                    (i) Sections 2.4, 2.5, 3.6, 3.8, 6.3 and 6.7 of the Gilead License;

                    (ii) Sections 4.3 and 4.4 of the Isis License; and

                    (iii) Sections 2.3, 3.2, 3.5, 4.1, 4.9, 8.1, 8.2.3, 9.1 and 9.6 of the Nektar License.

               (c) Any sublicensee obligations required by the Gilead License, the Isis License and the
Nektar License to be included in a sublicense thereunder, including without limitation any required
provision making the applicable Eyetech Third Party Licensor a third party beneficiary of any
sublicense thereunder, shall be deemed to be included in this Agreement.

               (d) The licenses granted by Eyetech in Section 3.1(a) with respect to the following patents:
US Patent No. 5,475,096, US Patent No. 5,670,637, and US Patent No. 5,696,249, are subject to 35
USC §§200-212, 37 CFR §401 et seq. and applicable governmental implementing regulations. Any right
granted in this Agreement greater than that permitted under 35 USC §§200-212 or 37 CFR §401 et seq.
shall be subject to modification as may be required to conform to the provisions of those statutes.
All rights reserved to the United States government and others under 35 USC §§200-212 and 37 CFR
§401 shall remain and shall in no way be affected by this Agreement.

15

 

          3.2 License Grant to Eyetech. Subject to the terms of this Agreement, Pfizer hereby
grants to Eyetech, and Eyetech hereby accepts, (i) an exclusive (even as to Pfizer, subject to a
retained right by Pfizer to develop, use, make, have made and import the Product in the US
Territory solely for the purpose of obtaining regulatory approval(s) for the Product in the ROW
Territory and developing and supplying the Product for sale and importation in the ROW Territory),
royalty-free license under the Pfizer Patent Rights, Pfizer Technical Information, and Pfizer’s
rights under any Joint Patent Rights and Ongoing Trial Data, to develop, use, make, have made,
sell, offer for sale, import, and have imported the Product in the US Territory, and (ii) a
nonexclusive, royalty-free license under the Pfizer Patent Rights and corresponding ROW Territory
Patent Rights owned or Controlled by Pfizer or its Affiliates, Pfizer Technical Information, and
Pfizer’s rights under any Joint Patent Rights and Ongoing Trial Data, to develop, use, make, have
made and import the Product in the ROW Territory solely for the purpose of developing and supplying
the Product for sale and importation in the US Territory.

          3.3 Sublicensing.

               (a) The licenses granted in Sections 3.1(a) and 3.2 above include the right by either Party to
grant sublicenses. Any sublicense granted by a Party must be granted pursuant to a written
agreement that subjects the sublicensee to all relevant restrictions, limitations and obligations
in this Agreement.

               (b) If a Party grants a sublicense under Section 3.3(a), such Party shall be responsible for
failure by its sublicensees to comply with all relevant restrictions, limitations and obligations
in this Agreement.

               (c) In the event of a material default by any sublicensee under a sublicense agreement, the
sublicensing Party will inform the other Party and take such action, after

16

 

consultation with the other Party, that in the sublicensing Party’s reasonable business
judgment is required to address such default.

               (d) Pfizer shall provide Eyetech with a copy of each sublicense agreement, in final executed
form, that Pfizer enters into in accordance with this Section 3.3 not later than five (5) days
after the execution of such sublicense agreement; provided that Pfizer may redact
the financial terms from such copies only if permitted under the applicable requirements of the
Gilead License, the Nektar License and the Isis License requiring delivery to Gilead, Nektar or
Isis of copies of sublicense agreements.

          3.4 Product Orders or Sales Outside of a Party’s Territory. If Eyetech receives an
order for the Product from a third party that is either located in the ROW Territory or that
intends to resell the Product into the ROW Territory, Eyetech will not accept such order and shall
refer such order to Pfizer. If Pfizer receives an order for the Product from a third party that is
either located in the US Territory or that intends to resell the Product into the US Territory,
Pfizer will not accept such order and shall refer such order to Eyetech. Each Party agrees that it
shall not, and shall cause its Affiliates and licensees or sublicensees not to, (a) solicit active
or passive sales of the Product outside of, in the case of Eyetech, the US Territory, and in the
case of Pfizer, the ROW Territory, or (b) sell the Product to a third party where the selling Party
knows or should reasonably know that such third party intends to resell such Product outside of, in
the case of Eyetech, the US Territory, and in the case of Pfizer, the ROW Territory.

          3.5 Right of First Negotiation For New Products. During the period commencing upon
the Restatement Date and ending upon the** anniversary of the Restatement Date (the
“ROFN Period”), in the event that Eyetech proposes to (a) commence a phase III clinical
trial with respect to any New Product that Eyetech intends will serve as a pivotal trial for the
purpose of obtaining

 

			
	**	 	This portion has been redacted pursuant to a
confidential treatment request.

17

 

regulatory approval(s) for such New Product in the ROW Territory, or (b) grant to any third
party any right or license under any Patent Rights Controlled by Eyetech or its Affiliates to offer
for sale, sell or have sold any New Product(s) in the ROW Territory, then Eyetech shall provide
Pfizer with (x) written notice thereof (“Notice of Opportunity”), and (y) any material
information regarding the toxicology, safety and efficacy of the New Product(s) identified in the
Notice of Opportunity (the ROW Territory commercialization rights with respect to each such
identified New Product(s), a “New Product Opportunity”), the status of any material
discussions with the FDA relating to such New Product, and any relevant patent information, each to
the extent that such information is available and permitted to be disclosed by Eyetech as of the
date of the Notice of Opportunity. In the case of the foregoing clause (a), Eyetech shall provide
Pfizer with the Notice of Opportunity during the time period commencing upon** and
ending with **. In the case of the foregoing clause (b), Eyetech shall provide Pfizer
with the Notice of Opportunity on or about the time at which **. Pfizer, at its option,
will have the right to negotiate with Eyetech for rights to the New Product Opportunity and to
expand Pfizer’s license hereunder to include rights to such New Product Opportunity;
provided that Pfizer exercises such right by written notice to Eyetech within
** days after receipt of the Notice of Opportunity. In the event that Pfizer does not
provide the written notice exercising Pfizer’s right to negotiate as described in the immediately
preceding sentence, Eyetech shall have no further obligation to Pfizer, and Pfizer shall have no
further rights, with respect to such New Product Opportunity. In the event that Pfizer provides
the written notice exercising Pfizer’s right to negotiate as described above, Eyetech shall not
commence such phase III clinical trial of the applicable New Product(s) or grant rights to such New
Product Opportunity to a third party for a period of up to **, in order to provide
Pfizer with an opportunity to discuss with Eyetech the terms pursuant to which Pfizer would license
rights to such New Product

 

			
	**	 	This portion has been redacted pursuant to a
confidential treatment request.

18

 

Opportunity. Pfizer’s rights under this Section 3.5 shall apply on a New Product
Opportunity-by-New Product Opportunity basis, and Pfizer’s waiver of its rights hereunder with
respect to any particular New Product Opportunity shall not constitute a waiver of such rights with
respect to any other New Product Opportunity. If the Parties do not reach agreement regarding the
terms on which Pfizer would license rights to any New Product Opportunity during any such
** negotiation period, Eyetech shall have no further obligation to Pfizer, and Pfizer
shall have no further rights, with respect to such New Product Opportunity; provided
that, (A) during the ROFN Period, Eyetech shall not grant any third party a license of any
Patent Rights Controlled by Eyetech or its Affiliates for such New Product Opportunity on terms
which, **, and (B) in the case of a New Product Opportunity for which Eyetech provided
Pfizer with a Notice of Opportunity pursuant to the foregoing clause (b), if Eyetech has not
granted rights to such New Product Opportunity to a third party within ** after the end
of such ** negotiation period between Eyetech and Pfizer, the provisions of this Section
3.5 shall once again apply to such New Product Opportunity.

ARTICLE 4

MANUFACTURING, MARKETING, MEDICAL AND REGULATORY MATTERS

          4.1 Meetings and Information Exchange. The Parties recognize that, after the
Restatement Date, it is critical to maintain and facilitate ongoing cooperation and information
exchange between them concerning the Product. Accordingly, representatives of the Parties shall
meet periodically as set forth in this Article 4 in order to exchange, assess and discuss
information and strategies related to, inter alia, the: (1) continued clinical development
of, and regulatory strategy for, the Product, (2) marketing and promotion for the Product, and (3)
manufacture, supply and distribution of the Product. These meetings may be held in person, by
videoconference or by

 

			
	**	 	This portion has been redacted pursuant to a
confidential treatment request.

19

 

teleconference, as the Parties mutually agree, and all in-person meetings shall be at
locations mutually agreed-upon by the Parties.

          4.2 Ongoing Clinical Trials. Schedule 4.2 sets forth a list of the ongoing
clinical trials for the Product (the “Ongoing Trials”), the identity of the Party
responsible for completing the trial and performing remaining activities for each such trial (the
“Responsible Party”), the allocation between the Parties of the future costs for performing
the activities for each such trial, which costs shall be reconciled between the Parties pursuant to
Section 5.2 hereof, and the services, if any, to be provided to the Responsible Party by the other
Party in connection with each Ongoing Trial. Each Party will cooperate with the other Party, at
the other Party’s reasonable request, in order to complete the Ongoing Trials. Except with respect
to the CRVO study (study number 1011), for which Eyetech will complete the final clinical study
report within one (1) year from completion of such study, the Responsible Party for a particular
Ongoing Trial shall have the right to change or terminate such Ongoing Trial as such Party may deem
necessary or desirable, provided, that the other Party shall not be liable for any such change or
termination and shall be compensated for such Party’s performance of any additional activities or
services requested by the Responsible Party in connection with such change or termination.
Services to be provided by Eyetech to Pfizer in connection with certain Ongoing Trials will be
provided pursuant to the Transitional Services Agreement. Any services to be provided by Pfizer to
Eyetech in connection with certain Ongoing Trials will be provided pursuant to the Amended and
Restated Regulatory Services Agreement. In addition,**. In addition, Pfizer shall
provide Eyetech access to, and shall reasonably cooperate with Eyetech in compiling, data that may
reasonably be deemed necessary by Eyetech to fulfill its post-marketing commitments to the FDA for
the Product with respect to ERG and corneal biomicroscopy, and to respond to related queries or
requests by the FDA with respect to such post-

 

			
	**	 	This portion has been redacted pursuant to a
confidential treatment request.

20

 

marketing commitments to the FDA. Without limiting the Parties’ rights and obligations under
the Pharmacovigilance Agreement with respect to the sharing of any clinical data thereunder, with
respect to each clinical trial for the Product completed prior to the Restatement Date as well as
each Ongoing Trial, Pfizer and Eyetech shall each provide, or cause any third party at which such
information is stored to provide, the other Party with all raw data and final results arising from
such trials promptly after such data and results become available, but no less frequently than on a
quarterly basis for the duration of any Ongoing Trials, provided that, if a Party
requests interim disclosure of Ongoing Trial Data in the possession of the other Party, the other
Party shall not unreasonably refuse to provide such interim disclosure. Each Party will provide
the other with a draft of all public releases of Ongoing Trial Data reasonably in advance of public
dissemination of any such release in order to afford the other Party with an opportunity to review
and comment upon such draft. The Party identified on Schedule 4.2 as the responsible party
for performing activities with respect to an Ongoing Trial may post the final results from such
Ongoing Trial on the PhRMA clinical studies database located at www.clinicalstudyresults.org.

          4.3 Future Clinical Trials. Subject to the remainder of this Section 4.3, and in
addition to the rights and obligations of the Parties as set forth in Section 4.7(d) below, Pfizer
has the right to conduct further clinical studies with respect to the Product in the ROW Territory,
and Eyetech has the right to conduct further clinical studies with respect to the Product in the US
Territory. At the request of either Party, the Parties shall in good faith meet and discuss
jointly conducting additional clinical studies with respect to the Product where preclinical and/or
clinical results **. If the Parties agree to pursue such additional development
jointly, the Parties shall agree on both the manner in which the costs for such development will be
shared, and each Party’s respective rights to use the data and other information resulting from
such development. If the Parties do not agree

 

			
	**	 	This portion has been redacted pursuant to a
confidential treatment request.

21

 

to jointly pursue such additional development, either Party shall have the right to pursue
such development at its sole expense; provided, however, that **.

          4.4 Marketing.

               (a) In order to ensure that a consistent message is communicated by the Parties with respect
to the Product, representatives of the Parties shall meet at least once each calendar quarter to
review and discuss their respective strategies for the advertising and promotion of the Product.

               (b) **

               (c) **

               (d) **

               (e) In connection with the marketing, promotion and medical support of the Product in the US
Territory, Pfizer and/or Eyetech (or its Affiliate) have entered into the third party agreements as
set forth in Schedule 4.4(e) (the “US Territory Agreements”). Subject to the terms
and conditions of such agreements and any required third party consents, Pfizer shall assign to
Eyetech, and Eyetech will assume, all of Pfizer’s rights and obligations under such US Territory
Agreements pursuant to the Assignment and Assumption Agreement for US Territory Agreements. For
the avoidance of doubt, if Pfizer is not permitted to assign all of its rights and obligations
under a US Territory Agreement to Eyetech, then such US Territory Agreement will be terminated by
Pfizer and/or Eyetech (or its Affiliate), as applicable.

               (f) With respect to ** in payments made by Pfizer as of the Restatement on behalf
of the Parties to ** to organize two (2) consultant meetings for Product in the US
Territory to be held after the Restatement Date and solely under the control of and for the benefit
of Eyetech,

 

			
	**	 	This portion has been redacted pursuant to a
confidential treatment request.

22

 

Eyetech shall reimburse Pfizer for the Out-of-Pocket Costs thereof. Such costs shall be
included in Pfizer’s Quarterly Expense Report.

               (g) In addition, the Parties further agree to:

                    (i) provide each other, for information, with a copy of all new advertising and promotional
materials for the Product produced by Eyetech for the US Territory and by Pfizer for all
English-speaking countries in the ROW Territory;

                    (ii) discuss, share information concerning, and, to the extent reasonably practicable,
coordinate, advisory board meetings, contacts with key opinion leaders, and activities at the
ARVO and AAO global congresses and the world ophthalmology conference (WOC) (collectively,
“Global Congresses”). The Parties will share their planning for all Global Congresses
with respect to the Product in advance of the applicable event. In addition, with respect to the
two (2) 10x10 Product-specific convention booths in existence as of the Restatement Date, from
and after the Restatement Date each Party shall own one (1) such booth as discussed by the
Parties prior to the Restatement Date and each Party agrees to execute any assignments and other
documents and take any further actions as may be necessary to more fully vest on the other Party
such agreed ownership.**

 

	**	 	This portion has been redacted pursuant to a confidential
treatment request.

23

 

                    (iii) coordinate press releases and other communications on new data or other material
information concerning the Product by providing drafts of all such press releases or
communications reasonably in advance of public dissemination of any of the foregoing in order to
afford the other Party with an opportunity to review and comment upon such draft in advance of
dissemination;

                    (iv) exchange, at least once each calendar year, a list of magazines, journals and other
publications in which it plans to place advertising for the Product and attempt, to the extent
reasonably practicable, to allocate advertising responsibility based on the country in which the
applicable magazine, journal or other publication maintains its primary circulation; and

                    (v) cooperate in the development of separate US Territory and ROW Territory Internet
websites for the Product. After the Restatement Date, Eyetech shall retain ownership of the
websites (including URL) currently located at “www.macugen.com” and “www.macugen.net”, shall
continue to operate, maintain and develop the “www.macugen.com” website for Product in the US
Territory, and shall be responsible for all costs associated

24

 

therewith. After the Restatement Date, Pfizer shall operate, maintain and develop the
website “www.macugen.net” for Product in the ROW Territory, and shall be responsible for all
costs associated therewith. Subject to the terms and conditions hereof, Eyetech shall maintain a
link on the “www.macugen.com” website to the “www.macugen.net” website, and Pfizer shall maintain
a link on the “www.macugen.net” website to the “www.macugen.com” website, such links to be in a
form to be mutually agreed by the Parties.

          4.5 Pharmacovigilance and Product Safety Matters. Eyetech and Pfizer shall be
responsible for the surveillance, receipt, evaluation, and reporting of adverse drug experiences
for the Product in the US Territory and the ROW Territory, respectively, and, with respect to the
exchange of adverse event and other safety information relating to the Product, each shall at all
times comply with the terms of the Pharmacovigilance Agreement between the Parties dated May 11,
2006 (as it may be amended from time to time, the “Pharmacovigilance Agreement”). Pursuant
to the Pharmacovigilance Agreement, Pfizer is currently responsible for receipt, processing,
evaluation and follow-up of all post-marketing reports for the US Territory. Eyetech has requested
that Pfizer, and Pfizer has agreed to, continue to be responsible for receipt, processing,
evaluation and follow-up of all post-marketing reports for the US Territory for a period of
** after the Restatement Date. The Pharmacovigilance Agreement will be amended to
reflect such transfer of any responsibilities from Pfizer to Eyetech or its successor.

          4.6 Medical Information and Product Complaints. Eyetech shall be responsible for
responding to medical, consumer and other inquiries received from the US Territory concerning the
Product, including any Product complaints, and, subject to the services to be provided by Pfizer to
Eyetech pursuant to the Amended and Restated Regulatory Services Agreement, Pfizer shall direct all
such matters to Eyetech’s attention. Pfizer shall be responsible for responding to medical,

 

			
	**	 	This portion has been redacted pursuant to a
confidential treatment request.

25

 

consumer and other inquiries received from the ROW Territory concerning the Product, including
any Product complaints, and Eyetech shall direct all such matters to Pfizer’s attention. The
Parties acknowledge that, as of the Restatement Date, Pfizer is handling certain Product complaints
and medical, consumer and other inquiries concerning the Product on behalf of Eyetech for the US
Territory. Eyetech shall have the right to request that Pfizer continue to handle these matters
for the US Territory pursuant to, and subject to the terms of, the Amended and Restated Regulatory
Services Agreement.

          4.7 Regulatory Matters. All regulatory approvals in the ROW Territory relating to the
Product shall continue to be the property of Pfizer and held in Pfizer’s or its Affiliate’s name,
and all regulatory approvals in the US Territory shall continue to be the property of Eyetech and
held in Eyetech’s or its Affiliate’s name. Each Party will cooperate with the other, and provide
the other with reasonable assistance, in connection with future filings with Governmental
Authorities concerning the Product (including filings related to regulatory approval or safety of,
or approval of a new indication for, the Product, but excluding DDMAC filings), in each case at the
owning Party’s request and expense, including without limitation by (i) providing reasonable
assistance to such owning Party to provide information to, and answer queries posed by, Regulatory
Authorities in connection with obtaining or maintaining regulatory approvals for Product, (ii)
providing, or causing its third party contractors to provide, the owning Party with non-clinical
data concerning the Product including CMC, pharmacology, toxicology, and pharmacodynamics data; and
(iii) permitting the applicable Governmental Authorities to inspect manufacturing or testing
facilities of the non-owning party as required by such Governmental Authorities. In addition, the
Parties agree as follows with respect to future regulatory activities concerning the Product:

26

 

               (a) Each Party will provide the other Party with copies of all material Product-related
correspondence that it receives from the FDA or analogous Governmental Authorities or Regulatory
Authorities in the European Union, Canada and Japan, except correspondence from DDMAC. In addition
to the immediately preceding sentence and to Section 4.1, each Party will provide the other Party
with copies, which copies may be in draft form, of (i) the safety sections of material
Product-related submissions to the FDA or analogous Governmental Authorities or Regulatory
Authorities in the ROW Territory, and (ii) any sections disclosing or concerning any Ongoing Trial
Data included in any such submissions, reasonably in advance of submission, and such Party shall,
prior to making such submission, reasonably consider the comments, if any, given by the other
Party; and

               (b) Any decision to initiate a recall or withdrawal of, or a broad-based non-promotional
information update to physicians about (e.g., a “Dear Dr. Letter”), the Product in the US Territory
shall be made by Eyetech and any decision to initiate a recall or withdrawal of, or a broad-based
non-promotional information update to physicians about, the Product in the ROW Territory shall be
made by Pfizer. Before either Party initiates a recall, withdrawal or broad-based non-promotional
information update to physicians about the Product, such Party shall, if reasonably practicable
under the circumstances, promptly and in good faith discuss the reasons therefor with the other.
In the event of any recall or withdrawal of, or broad-based non-promotional information update to
physicians about, the Product in the US Territory, Eyetech shall be responsible for implementing
any necessary action and the associated costs thereof, and in the event of any recall or withdrawal
of, or broad-based non-promotional information update to physicians about, the Product in the ROW
Territory, Pfizer shall be responsible for implementing any necessary action and the associated
costs thereof.

27

 

               (c) Pfizer will provide certain services relating to the US Territory during a transitional
period pursuant to the Amended and Restated Regulatory Services Agreement. The fees payable to
Pfizer by Eyetech for the services provided by Pfizer under the Amended and Restated Regulatory
Services Agreement shall be included in Pfizer’s Quarterly Expense Report.

               (d) Notwithstanding Section 4.2, Section 4.3 or the exclusive grant of rights to Pfizer in
Section 3.1(a) and to Eyetech in Section 3.2, Eyetech may open one or more clinical trial sites in
the ROW Territory and Pfizer may open one or more clinical trial sites in the US Territory, solely
in connection with clinical studies for the Product, the results of which are intended for
Eyetech’s use solely in the US Territory or Pfizer’s use solely in the ROW Territory, as
applicable. In the event that a Party intends to open any clinical trial sites in the other
Party’s Territory, such Party will provide the other Party with written notice thereof, a copy of
the protocol for the clinical study, a list of the investigators, and any other documents or
information required by local Regulatory Authorities in such Territory. Pfizer will be solely
responsible for submitting the foregoing to the applicable Regulatory Authorities in the ROW
Territory and for any other communications with the applicable Regulatory Authorities in the ROW
Territory concerning any such Eyetech clinical study, and Eyetech will be solely responsible for
submitting the foregoing to the applicable Regulatory Authorities in the US Territory and for any
other communications with the applicable Regulatory Authorities in the US Territory concerning any
such Pfizer clinical study. Without limiting the generality of the foregoing, Eyetech shall have
the right to reference Pfizer’s clinical trial authorizations concerning the Product for purposes
of establishing and conducting such clinical trial sites in the ROW Territory, and Pfizer shall
have the right to reference Eyetech’s Investigational New Drug applications for Product for
purposes of establishing and conducting such clinical trial sites in the US Territory.

28

 

          4.8 Scientific Activities; Investigator Initiated Research; Medical Education Grants.
The Parties recognize that close coordination and sharing of information with respect to proposed
scientific and medical publications is critical for the future success of the Product.
Accordingly, to the extent reasonably practicable, each Party agrees to: (a) provide the other
Party with a draft of all Product-related scientific publications proposed for submission by such
Party (“Proposed Submissions”), including manuscripts and meeting abstracts, prior to such
submission; and (b) meet on a regular basis, but no less than**, to discuss, with
respect to the Product, proposed, completed or otherwise finalized investigator-initiated research,
medical education grants, and each Party’s planned or finalized publications, abstracts and oral
presentations; provided that, in the absence of an agreement between the Parties to
the contrary, no such sharing of information shall entitle the receiving Party to use any data
conferred therein or to exercise any approval right over the other Party’s Proposed Submissions.
For the avoidance of doubt, (x) Eyetech shall have the sole right, but not the obligation, to fund
investigator-initiated research and medical education grants concerning the Product or related
disease state education in both the US Territory and the ROW Territory, provided that any such
funding directly concerning the Product in the ROW Territory is solely to support Eyetech’s
activities in the US Territory, and (y) Pfizer shall have the sole right, but not the obligation,
to fund investigator-initiated research and medical education grants concerning the Product or
related disease state education in both the ROW Territory and the US Territory, provided that any
such funding directly concerning the Product in the US Territory is solely to support Pfizer’s
activities in the ROW Territory. Each Party shall notify the other Party prior to commencement of
any investigator-initiated research funded by the notifying Party in such other Party’s Territory,
in order to provide such other Party with an opportunity to provide, at such other Party’s
discretion, feedback to the notifying Party concerning such proposed research.

 

			
	**	 	This portion has been redacted pursuant to a
confidential treatment request.

29

 

          4.9 Manufacturing and Supply.

               (a) Representatives of the Parties will meet at least ** (until such time as
otherwise mutually agreed by the Parties) in order to discuss (i) worldwide quality assurance to
ensure that all bulk drug substance and starting materials (together, “Product Components”)
and Product are manufactured in accordance with the Parties’ quality standards; (ii) supply
relationships with third party manufacturers; (iii) any changes required by Law to the approved
specifications for the Product or any Product Component; and (iv) forecasts for the Product and
Product Components and inventory levels for the Product and Product Components, and future logistic
strategies and capacity planning.

               (b) As of the Restatement Date, Eyetech shall assign to Pfizer, subject to receipt of any
required third party consents or approvals required as a condition to such assignment (the
“Required Consents”), each of the agreements set forth in Schedule 4.9(b) pursuant
to the Assignment and Assumption Agreement for Manufacturing Agreements. If the Parties are not
able to procure a Required Consent, then Eyetech shall continue to provide Pfizer with the benefit
of the contract with the third party that refused to provide the Required Consent pursuant to the
Transitional Services Agreement between Eyetech and Pfizer. The Parties acknowledge and agree
that, subject to obtaining Required Consent with respect to the assignment of the Degussa Agreement
to Pfizer, and after the date on which such Required Consent is obtained (“Assignment
Date”):

                    (i) **

                    (ii) Pfizer shall, and hereby does, grant to Eyetech a sublicense of Pfizer’s rights under
Section 2.3(c) of the Degussa Agreement, effective upon the Assignment Date;

 

			
	**	 	This portion has been redacted pursuant to a
confidential treatment request.

30

 

                    (iii) Pfizer shall not amend the Degussa Agreement or grant to any third party any rights
thereunder in any manner that would prevent, be inconsistent with, or otherwise undermine the
benefit to Eyetech of, the license grants to Eyetech set forth in the immediately preceding clauses
(i) and (ii) above;

                    (iv) **

                    (v) In the event that Eyetech’s authorization is required in order for Degussa or its third
party subcontractor to use certain protocols (“Eyetech Protocols”) to test API and/or
Eyetech Product, or any component thereof, on behalf of Pfizer under the Degussa Agreement, Eyetech
shall provide such authorization, provided, however, that in no event shall
Eyetech be liable for any use or non-use of such Eyetech Protocols.

               The Parties further acknowledge and agree that there may be other agreements related to
manufacturing and/or quality assurance of Product to which Eyetech and/or Pfizer may be party(ies)
and which may need to be amended or otherwise addressed following the Restatement Date in
connection with the transactions contemplated under this Agreement, and each Party shall cooperate
with the other Party in undertaking such amendments or other actions.

               (c) Each Party will be responsible for ** (**%) of (x)**; (y)
Out-of-Pocket Costs of retesting Current Inventories and Other Components; and (z) obsolescence,
destruction and disposal costs, if any, for portions of the Current Inventories and Other
Components that become unusable. “Current Inventories” means the inventories owned by the
Parties on the Restatement Date of (1) bulk drug substance; and (2) finished goods. ** The lot
number, unit cost, number of units, and Territorial designation of the Current Inventories as of
April 9, 2007, with respect to finished goods, and the Restatement Date with respect to bulk drug
substance are reflected on Schedule 4.9(c). Promptly after the Restatement Date, the
Parties shall update Schedule 4.9(c) to

 

			
	**	 	This portion has been redacted pursuant to a
confidential treatment request.

31

 

account for Current Inventories of finished goods as of the Restatement Date. After the
Restatement Date, each Party will own all Current Inventories manufactured for such Party’s
Territory. Eyetech will, and hereby does, transfer to Pfizer title to all the starting materials
for manufacture of the bulk drug substance for Product in inventory as of the Restatement Date (the
“Other Components”) pursuant to the Bill of Sale. The inventory of, and Eyetech’s direct,
out-of-pocket costs for, Other Components as of the Restatement Date are set forth on Schedule
4.9(c). Within ** days after the Restatement Date, Pfizer shall pay Eyetech for
Eyetech’s direct, out-of-pocket costs for Other Components as of the Restatement Date. If and when
any materials contained in either Party’s Current Inventories or Other Components (which, for
purposes of clarity, shall include, with respect to Pfizer, the Other Components transferred to
Pfizer pursuant to this Section 4.9(c)) are deemed by such Party, based on relevant factors
including expiration date, results of retesting, non-conformance with Product specifications in
such Party’s Territory, or such Party’s internal quality standards, to be unusable, such Party will
provide notice to the other Party describing the materials within the Current Inventories and Other
Components that such Party has deemed to be unusable. Any amounts for which either Party is
entitled to contribution from the other Party pursuant to Section 4.9(c) will be included in such
Party’s Quarterly Expense Report.

               (d) The Parties acknowledge and agree that Pfizer currently holds an inventory of certain
pre-printed syringes and related components (“BD Luer Lok Preprinted Syringes”) which were
purchased by Pfizer to support certain line trials and qualification runs, and that, to the extent
that any such BD Luer Lok Preprinted Syringes remain unused after the completion of such line
trials and qualification runs, Pfizer shall notify Eyetech of such remaining BD Luer Lok Preprinted
Syringes and Pfizer’s Out-of-Pocket Costs for procuring such BD Luer Lok Preprinted Syringes from
the relevant third party vendor. To the extent requested by Eyetech, Pfizer will transfer title

 

			
	**	 	This portion has been redacted pursuant to a
confidential treatment request.

32

 

to, and Eyetech shall purchase, all such remaining BD Luer Lok Preprinted Syringes, at
Pfizer’s Out-of-Pocket Costs for procuring such BD Luer Lok Preprinted Syringes.

               (e) Eyetech shall provide Pfizer, upon Pfizer’s reasonable request, with copies of data and
documentation in Eyetech’s possession or under Eyetech’s control, which data and documentation
relate to the manufacture, process development and validation of Product Components or the Product.

               (f) Pursuant to the Bill of Sale, Eyetech shall transfer to Pfizer title to capital equipment
purchased by Eyetech for the manufacture of bulk drug substance for Product at Degussa, which
equipment is owned by Eyetech and held in Eyetech’s name (“Eyetech Capital Equipment”);
provided, that in the event that such transfer does not occur prior to or as of the
Restatement Date, Pfizer will be entitled to use, and to enjoy all of the benefits of, such Eyetech
Capital Equipment in connection with the manufacture of bulk drug substance for Product until such
transfer has occurred.

               (g) With respect to capital equipment required for the manufacture of finished Product at
Gilead and purchased, or to be purchased, by Pfizer, which equipment is or shall be owned by Pfizer
and held in Pfizer’s name and set forth on Schedule 4.9(g) (“Pfizer Capital
Equipment”), Eyetech shall be financially responsible for **% and Pfizer for
**% of the capital expenditures for such Pfizer Capital Equipment, together with the
costs of the services related thereto. For the avoidance of doubt, the above allocation of
financial responsibility shall apply to ** . The budget for the capital expenditure
amounts for Pfizer Capital Equipment and ** are set forth on Schedule 4.9(g),
which shall be updated by the Parties promptly after the Restatement Date to reflect an updated
budget and statement of costs of services related to the Pfizer Capital Equipment as of the
Restatement Date. Pfizer will charge Eyetech for Eyetech’s share of the cost

 

			
	**	 	This portion has been redacted pursuant to a
confidential treatment request.

33

 

of such Pfizer Capital Equipment and related services in Pfizer’s Quarterly Expense Report.
Title to the Pfizer Capital Equipment installed, or to be installed, at Gilead shall remain with
Pfizer; provided, however, that Eyetech will be entitled to use, and to enjoy all
of the benefits of, such Pfizer Capital Equipment in connection with the manufacture of finished
Product.

          4.10 Analytical and Other Support Services. Pursuant to the Transitional Services
Agreement, Eyetech shall provide to Pfizer certain services, including stability and analytical
services related to the Product and Product Components, which services are currently, or have been,
provided to Pfizer by Eyetech using Eyetech’s Cedar Knolls, New Jersey facility. The costs of the
transitional services provided by Eyetech under the Transitional Services Agreement shall be
included in Eyetech’s Quarterly Expense Report.

          4.11 Distribution. Pfizer will continue to provide certain logistics services to
Eyetech with respect to the distribution of the Product in the US Territory pursuant to the Amended
and Restated Distribution Agreement. The cost of the services provided by Pfizer under the Amended
and Restated Distribution Agreement shall be included in Pfizer’s Quarterly Expense Report.

ARTICLE 5

COST SHARING

          5.1 Responsibility for Expenses. Other than as mutually agreed-upon by the Parties,
or as otherwise set forth in this Agreement or any Exhibit or Schedule to this Agreement, after the
Restatement Date, Pfizer will be responsible for 100% of the internal and external development,
marketing, regulatory expenses, and cost of goods sold, relating to the sale of Product in the ROW
Territory, and Eyetech will be responsible for 100% of the internal and external development,
marketing, regulatory costs, and cost of goods sold, relating to the sale of Product in the US

34

 

Territory. Promptly, but no later than ** after the Restatement Date, the Parties
will perform a preliminary reconciliation pursuant to the Collaboration Agreement in order to
settle all expense and Net Sales sharing with respect to the Product under the Prior Agreements and
the Original License Agreement for all periods prior to the Restatement Date, and a final
reconciliation to settle all such expense and Net Sales sharing no later than ** after
the Restatement Date.

          5.2 Reconciliation of Expenses.

               (a) Within ** days after the end of each calendar quarter during the term of this
Agreement, each Party shall provide the other Party with a statement of the expenses relating to
the Product, if any, incurred by such Party during such calendar quarter (or, with respect to the
first such reconciliation, all prior periods following the Restatement Date through the end of such
calendar quarter) for which such Party is entitled to reimbursement from the other Party pursuant
to this Agreement or any other Transaction Agreement, as well as the details of adjustments, if
any, to be made to the amounts submitted by such Party for previous calendar quarters (such
reports, “Quarterly Expense Reports”). The Quarterly Expense Reports shall be
substantially in the form of Exhibit 5.2(a) to this Agreement.

               (b) The Party entitled to receive payment from the other Party, as set forth in the report
prepared and delivered in accordance with Section 5.2(a) shall issue an invoice to the other Party
reflecting the net amount payable, and such amount shall be paid by the Party owing such net amount
to the other Party within ** after such invoice is delivered.

          5.3 Offset. Any amount payable by either Party pursuant to Section 5.1 or 5.2 may be
offset against any other amounts then payable to such Party under this Agreement or any other
Transaction Agreement.

 

			
	**	 	This portion has been redacted pursuant to a
confidential treatment request.

35

 

ARTICLE 6

THIRD PARTY ROYALTIES

          6.1 Payment of Third Party Royalties.

               (a) Pfizer shall be responsible for all royalties payable to third parties based on sales of
the Product in the ROW Territory. For the avoidance of doubt, in the event that any withholding or
other taxes are payable by Pfizer on any such payments due to the Eyetech Third Party Licensors
with respect to sales in the ROW Territory, then Pfizer shall make such tax payments in addition to
making the payments to Eyetech set forth in the immediately preceding sentence. If any withholding
or other taxes are payable by Eyetech on any such payments due to the Eyetech Third Party Licensors
with respect to sales in the ROW Territory, and such taxes are not deductible from the royalty
payments due to the Eyetech Third Party Licensors, then Pfizer shall pay to Eyetech an additional
amount equal to such taxes. Pfizer shall indemnify Eyetech and its Affiliates and their respective
directors, officers, employees and agents from and against any liability with respect to
withholding or other taxes that are payable by Pfizer or Eyetech on any royalty payments due to
Eyetech Third Party Licensors with respect to sales in the ROW Territory. The Parties shall
establish such procedures as are reasonably necessary to permit them to reconcile Eyetech’s actual
payments to the Eyetech Third Party Licensors with Pfizer’s payments to Eyetech under this Section
6.1. Notwithstanding the foregoing provisions of this Section 6.1, Pfizer shall not have any
responsibility for withholding taxes that become payable solely as a result of an assignment by
Eyetech of Eyetech’s rights to receive payments from Pfizer to an Affiliate of Eyetech or other
third party.

               (b) With respect to Pfizer’s responsibility for the payments of royalties payable by Eyetech
to Eyetech Third Party Licensors payable based on Net Sales of the Product in the ROW Territory,
Eyetech shall send Pfizer an invoice that shall be based on Pfizer’s report of Net

36

 

Sales pursuant to Section 6.2, and Pfizer will pay the amount reflected on such invoice within
** after such invoice is delivered by Eyetech. For the purposes of determining the
amount of third party royalties due for the relevant Pfizer Quarter, the amount of Net Sales in any
foreign currency shall be converted by Pfizer into United States dollars in a manner consistent
with Pfizer’s normal practices used to prepare its audited financial reports; provided
that such practices use a widely accepted source of published exchange rates.

          6.2 Net Sales Reports. Pfizer shall provide Eyetech with a report of Net Sales with
respect to each Pfizer Quarter within ** after the end of each calendar quarter, which report shall
identify, on a country-by-country basis, the Product and the Net Sales of each such Product;
** . Net Sales reports shall be kept confidential by Eyetech and not disclosed to any
other party other than Eyetech Third Party Licensors and their respective accountants and Boards of
Directors.

ARTICLE 7

PAYMENT TERMS; RECORD-KEEPING; AUDIT RIGHTS

          7.1 Payment Currency. All amounts due under this Agreement shall be paid to the
designated Party in United States dollars.

          7.2 Payments. All payments under this Agreement shall be made on or before the due
date by electronic transfer in immediately available funds to the respective account designated in
writing by each Party at least five (5) Business Days before the payment is due. All payments
under this Agreement shall bear interest from the date due until paid at a rate equal to the prime
rate of Citibank, NA as announced on the date such payment was due plus three percent (3%),
compounded on a calendar quarterly basis. In addition, the Party liable for late payment shall
reimburse the other Party for all reasonable costs and expenses, including without limitation
reasonable attorneys’ fees and legal expenses, incurred in the collection of late payments.

 

			
	**	 	This portion has been redacted pursuant to a
confidential treatment request.

37

 

          7.3 Books and Records. Each Party shall keep comprehensive books and records relating
to this Agreement in accordance with GAAP. Such books and records shall include all information
subject to audit pursuant to Section 7.4 including all expenses incurred or paid and any other
costs incurred for which the other Party is responsible pursuant to this Agreement, and in the case
of Pfizer, all books and records setting forth gross sales and Net Sales in the ROW Territory. All
such books and records shall be maintained for three (3) Years following the relevant Year or such
longer period as is required by Law.

          7.4 Audits. These audit and adjustment provisions apply with respect to all payments
due from one Party to another pursuant to this Agreement. Each Party shall have the right to have
the applicable books and records of the other Party audited by a nationally recognized independent
certified public accountant, selected by a Party (as to which firm the other Party has no
reasonable objection), under appropriate confidentiality provisions reasonably acceptable to the
accounting firm conducting the audit, for the sole purpose of verifying the accuracy of all
financial, accounting and numerical information and calculations under this Agreement. Any such
audit shall be conducted no more than once each Year during the term of this Agreement, shall be
limited to payments due within the prior three (3) Years, and shall be conducted upon at least
thirty (30) days’ advance notice during normal business hours and in a manner that does not
interfere unreasonably with the business of the audited entity. The results of any such audit shall
be delivered in writing to each Party and shall be binding absent manifest error. Any underpayment
or overbilling determined by such audit shall promptly be paid or refunded by the audited Party.
If the audited Party has underpaid or overbilled amounts due under this Agreement by more than five
percent (5%) over any reporting period, the audited Party shall also reimburse the other Party for
the cost of such audit (with the cost of the audit to be paid by the auditing Party in all other
cases),

38

 

plus interest at the interest rate set forth in Section 7.2, from the date of any such
underpayment or overpayment.

ARTICLE 8

CONFIDENTIALITY AND PUBLICITY

          8.1 Confidentiality. During the term of this Agreement and for ** after
the termination of this Agreement, each Party shall maintain Confidential Information provided by
the other Party in confidence, and shall not disclose, divulge or otherwise communicate such
Confidential Information to others, or use it for any purpose other than as permitted under this
Agreement. The receiving Party shall have the right to disclose Confidential Information received
from the other Party to Governmental Authorities to the extent reasonably required or desirable to
secure approval for marketing of the Product (provided that the receiving Party
shall use reasonable efforts to secure confidential treatment thereof), and to preclinical and
clinical investigators where reasonably necessary or desirable for their information to the extent
normal and usual in the custom of the trade and under a confidentiality agreement with provisions
governing confidentiality and non-use substantially the same as those contained herein.

          8.2 Publicity Related to this Agreement. The Parties recognize that each Party may
from time to time desire to issue press releases and make other public statements or disclosures
regarding the existence or terms of this Agreement. In such event, the Party desiring to issue a
press release or make a public statement or disclosure shall provide the other Party with a copy of
the proposed press release, statement or disclosure for review and approval in advance, which
advance approval shall not be unreasonably withheld, conditioned or delayed. No other public
statement or disclosure concerning the existence or terms of this Agreement shall be made, either
directly or indirectly, by either Party hereto, without first obtaining the written approval of the

 

			
	**	 	This portion has been redacted pursuant to a
confidential treatment request.

39

 

other Party. Once any public statement or disclosure has been approved in accordance with
this Section, then either Party may appropriately communicate information contained in such
permitted statement or disclosure. Notwithstanding the foregoing provisions of Section 8.1 or this
Section 8.2, a Party may (a) disclose the existence and terms of the this Agreement where required,
as reasonably determined by the disclosing Party, by applicable Law, by applicable stock exchange,
including Nasdaq, regulation or by order or other ruling of a competent court, and (b) disclose the
existence and terms of the this Agreement under obligations of confidentiality to agents, advisors,
contractors, investors and sublicensees, and to potential agents, advisors, contractors, investors
and sublicensees, in connection with such Party’s activities hereunder and in connection with such
Party’s financing activities, provided that, in the case of any such public
disclosure, the disclosing Party provides the other Party with a copy of the proposed text of such
announcement sufficiently in advance of the scheduled release or publication thereof to afford such
other Party a reasonable opportunity to review and comment upon the proposed text. Furthermore,
notwithstanding anything in this Agreement to the contrary, each Party shall have the right to
publicly announce or disclose, without having to first submit such announcement for review and/or
approval by the other Party, any information concerning such Party’s development and
commercialization of the Product in accordance with this Agreement, excluding any information
relating to the other Party or any arrangement with the other Party contemplated under this
Agreement (unless such information has already been approved by the other Party for public
disclosure).

          8.3 Applicability of Obligations to Affiliates, Employees, Directors, Agents, Independent
Contractors and Consultants. The confidentiality obligations of the Parties under this Article
8 shall be applicable to Parties, as well as their respective Affiliates, employees, directors,
agents, independent contractors and consultants.

40

 

ARTICLE 9

PATENTS AND TRADEMARKS

          9.1 Third Party License Agreements. The Parties acknowledge that the provisions of
this Article 9 are subject in all respects to the provisions of any license agreements between
Eyetech and Eyetech Third Party Licensors and the obligations of Eyetech and the rights of Pfizer
under this Article 9 are limited accordingly. Eyetech and Pfizer shall, within the foregoing
constraints, cooperate in the continued prosecution and maintenance by Eyetech or Gilead of the
Eyetech Patent Rights listed on Schedule 1.21 and licensed to Eyetech by Gilead.

          9.2 Disclosure of Patent Applications and Proceedings. Eyetech shall disclose to
Pfizer, within a reasonable time period prior to filing thereof, (i) the complete texts of all
national stage entry, continuation or divisional patent applications within the Eyetech Patent
Rights contemplated to be filed in the ROW Territory by Eyetech, or by Eyetech’s licensors to the
extent Eyetech is permitted to provide such texts to Pfizer under the terms of Eyetech’s agreements
with such licensors, and (ii) the complete texts of all US patent applications corresponding to the
Eyetech Patent Rights in the ROW Territory set forth in clause (i) above contemplated to be filed
in the US Territory by Eyetech, or by Eyetech’s licensors to the extent Eyetech is permitted to
provide such texts to Pfizer under the terms of Eyetech’s agreements with such licensors. Pfizer
shall have the right to review all such applications and make recommendations to Eyetech concerning
such applications, as well as the texts of any filed patent applications, information received
concerning the institution or possible institution of any opposition, revocation or any official
proceeding involving patents and patent applications within the Eyetech Patent Rights prosecuted
and/or maintained by Eyetech, or by Eyetech’s licensors to the extent Eyetech receives such
information, anywhere in the ROW Territory. Pfizer shall have the right to review all such
applications and other proceedings and make recommendations to Eyetech, and to Eyetech’s licensors
if permitted

41

 

under the terms of Eyetech’s agreements with such licensors, concerning such applications and
proceedings and their conduct. Eyetech agrees, subject to any limitations set forth in Eyetech’s
agreements with Eyetech’s licensors, to keep Pfizer promptly and fully informed of the course of
such patent prosecution and other proceedings including by providing Pfizer with copies of all
substantive communications submitted to or received from patent offices throughout the ROW
Territory and the US Territory. Pfizer shall provide such patent consultation at no cost to
Eyetech or its licensors, and shall hold all information disclosed to it under this Section 9.2 as
confidential subject to the provisions of Article 9 of this Agreement.

          9.3 Prosecution and Maintenance; Costs.

               (a) Eyetech shall not abandon any Eyetech Patent Rights in the ROW Territory with respect to
which Eyetech controls prosecution and maintenance activities, either directly or through step-in
rights granted to Eyetech in any third party license agreement, without at least 60 days’ prior
notice of such abandonment to Pfizer. If Eyetech decides to abandon any such Eyetech Patent Rights
in the ROW Territory, Pfizer shall have the option to continue the prosecution and maintenance of
such Eyetech Patent Rights in Eyetech’s name at Pfizer’s expense, subject to any limitations set
forth in Eyetech’s agreements with Eyetech’s licensors. If Pfizer desires that Eyetech file any
application within the Eyetech Patent Rights for a patent in specific countries in the ROW
Territory, or file any patent applications in the ROW Territory on improvements and variations upon
inventions disclosed in the Eyetech Patent Rights and relating to the Product, Pfizer shall advise
Eyetech of such countries or improvements, variations or inventions, as the case may be. Eyetech
shall consider Pfizer’s request in good faith and, unless Eyetech does not possess all legal rights
necessary to make such filing, Eyetech shall file the requested patent application, and Pfizer
shall pay all reasonable expenses, including reasonable fees for patent counsel, for filing

42

 

and for prosecuting such requested patent applications. Pfizer shall have reasonable access
to all documentation, filings and communications to or from the respective patent offices in the
ROW Territory with respect to such Eyetech Patent Rights, and shall be kept advised as to the
status of all pending applications to the extent pertaining to the Product in the ROW Territory and
to the extent Eyetech is able to provide such access, it being understood that all such
documentation, filings and communications shall constitute Confidential Information of Eyetech.
Pfizer shall be responsible for all of the Parties’ patent prosecution and maintenance costs
relating to the Eyetech Patent Rights in the ROW Territory. Pfizer shall reimburse Eyetech for all
such ROW Territory costs within thirty (30) days after receiving any invoice from Eyetech for such
costs.

               (b) With respect to Joint Patent Rights, the Parties agree to select outside counsel
acceptable to both Parties to file, prosecute and maintain such Joint Patent Rights in both
Parties’ names. Such outside counsel shall provide both Parties with copies of all substantive
correspondence and other communications from and with opportunities to review and comment in
advance on all substantive correspondence to and filings with any patent office relating to the
filing, prosecution and maintenance of such Joint Patent Rights. The costs, fees and expenses
related to the filing, prosecution and maintenance of Joint Patent Rights in the US Territory shall
be paid by Eyetech and in the ROW Territory shall be paid by Pfizer.

          9.4 Third Party Infringement Actions.

               (a) If any third party shall in the reasonable opinion of either Party, within any country in
the ROW Territory, infringe any Eyetech Patent Rights through infringing activities in the Field,
the Party learning of such infringement shall promptly notify the other Party and provide it with
any available evidence of such possible infringement. As between Pfizer and Eyetech, and subject
to any rights retained by Eyetech’s licensors, Pfizer shall have the first right to bring suit

43

 

and to take action against such infringer in its own name, or in the name of Eyetech (or
Eyetech’s licensor, to the extent Eyetech possesses the rights necessary to enable Pfizer to join
such licensor under the terms of Eyetech’s license agreement with such licensor; provided
that Eyetech shall have no liability for any failure of such licensor to appear or
cooperate in such action) where necessary, in which case Pfizer shall control the prosecution of
any such suit or claim, including without limitation the choice of counsel, and shall have the
exclusive right to settle or dispose of any such suit or claim. Notwithstanding anything to the
contrary in this Section 9.4, but subject to any legal obligations of Eyetech to its licensors with
respect to Eyetech Patent Rights, if Pfizer fails to initiate a suit or take other appropriate
action that it has the initial right to initiate or take pursuant to this Section 9.4 within ninety
(90) days after becoming aware of the basis for such suit or action, then Eyetech may, in its
discretion, provide Pfizer with written notice of Eyetech’s intent to initiate a suit or take other
appropriate action. If Eyetech provides such notice and Pfizer fails to initiate a suit or take
such other appropriate action within thirty (30) days after receipt of such notice from Eyetech,
then Eyetech shall have the right to initiate a suit or take other appropriate action that it
believes is reasonably required to protect the intellectual property rights at issue. The proceeds
of any recovery, court award or settlement of such action shall, after any required payments to
Eyetech’s licensors, first be applied to reimburse the Parties for the costs and expenses of such
prosecution and the balance shall be paid to the Party that initiated the suit or action.

               (b) If any third party shall in the reasonable opinion of either Party, within any country in
the other Party’s Territory, infringe any Joint Patent Rights through the manufacture, use, offer
for sale, sale or importation of a product that is, or is reasonably likely to be, competitive with
any Product that such other Party has rights to commercialize in such other Party’s Territory, such
Party shall promptly notify the other Party and provide it with any available evidence of such

44

 

possible infringement. The Party having rights to commercialize the applicable Product in
such Territory shall have the right to bring a suit or take other appropriate action with respect
to such infringement of Joint Patent Rights in such Territory. The proceeds of any recovery, court
award or settlement of such action shall be paid to the Party that initiated such suit or action.

          9.5 Patent Term Extensions. The Parties shall cooperate, if necessary and
appropriate, with each other in gaining patent term extension wherever applicable to Eyetech Patent
Rights in the ROW Territory. The Parties shall, if necessary and appropriate, use reasonable
efforts to agree upon a joint strategy relating to patent term extensions, but, in the absence of
mutual agreement, Pfizer will have final decision-making authority over extension of any Eyetech
Patent Right in the ROW Territory. Pfizer shall be responsible for the costs of seeking and/or
obtaining patent term extensions relating to such Eyetech Patent Rights in the ROW Territory.

          9.6 Product Labeling. In the ROW Territory, subject to Section 9.8, Pfizer shall be
the only Party identified on all Product package inserts, trade packages, packaging, samples, and
marketing and promotional materials.

          9.7 Pfizer Trademark. For a period not to exceed ** after the Restatement
Date, except with respect to Product inventory and packaging for, or any materials or articles
accompanying or affixed to, the Product existing or in-process as of the Restatement Date
(collectively, “Packaging Materials”), for which such period shall not exceed **
after the Restatement Date, Pfizer grants to Eyetech the non-exclusive right, free of charge, to
use the Pfizer name and logo in the US Territory solely in connection with the packaging, sale,
marketing, advertising, disposition and distribution of Product, Packaging Materials or advertising
and promotional materials, in each case that were in existence as of the Restatement Date, but only
to the extent the Pfizer name and logo were used by Eyetech for such purposes prior to the
Restatement Date in connection with the Product. The

 

			
	**	 	This portion has been redacted pursuant to a
confidential treatment request.

45

 

purpose of the license granted in this Section 9.7 is to provide Eyetech with a reasonable
transitional period in which to prepare materials for the packaging, sale, marketing, advertising,
disposition and distribution of the Product in the US Territory that do not contain the Pfizer name
or logo. Eyetech agrees to use its commercially reasonable efforts to discontinue its use of
Pfizer’s name and logo as soon as commercially practicable after the Restatement Date.

          9.8 Trademarks. For the term of this Agreement, Eyetech grants to Pfizer the
non-exclusive right, free of charge, to use the Trademarks in the ROW Territory solely for purposes
of marketing and promoting Product in the ROW Territory in accordance with this Agreement. For a
period of ** after the Reinstatement Date, Eyetech also grants to Pfizer the
non-exclusive right, free of charge, to use the Eyetech name and logo in the ROW Territory solely
for purposes of packaging, distributing, marketing and promoting Product in the ROW Territory in
accordance with this Agreement, but only to the extent that (a) the Eyetech name and logo were used
by Pfizer for such purposes prior to the Restatement Date in connection with the Product, and (b)
Pfizer uses its commercially reasonable efforts to discontinue its use of the Eyetech name and logo
as soon as commercially practicable after the Restatement Date. If Pfizer reasonably determines
that, despite such commercially reasonable efforts, applicable Law in the ROW Territory requires
Pfizer to continue to use the Eyetech name and logo beyond the ** period, then such
** period shall be extended until such time as Pfizer is able to discontinue Pfizer’s
use of the Eyetech name and logo in the ROW Territory without violating applicable Law,
provided, that Pfizer shall continue to use commercially reasonable efforts to
effect such discontinuance, including without limitation obtaining all required approvals from
Regulatory Authorities or Governmental Authorities in the ROW Territory, as soon as commercially
practicable within such extended period of time.

 

			
	**	 	This portion has been redacted pursuant to a
confidential treatment request.

46

 

          9.9 Trademark Ownership. Eyetech shall remain the owner of the Eyetech name and logo
and the Trademarks and the goodwill pertaining thereto, and Pfizer shall remain the owner of the
Pfizer name and logo and the MACUVERSE trademark and the goodwill pertaining thereto. Eyetech
shall be solely responsible for registering and maintaining the Eyetech name and logo and the
Trademarks in the ROW Territory. Except as contemplated herein, Eyetech shall have no rights in or
to the Pfizer name or logo or MACUVERSE trademark or the goodwill pertaining thereto. Except as
contemplated herein, Pfizer shall have no rights in the Eyetech name or logo or Trademarks or the
goodwill pertaining thereto. It is the Parties’ intention to utilize a single trademark for the
Product throughout the Territory. Accordingly, Pfizer agrees to use the Trademarks for the Product
in the ROW Territory, provided, however, if any Governmental Authority fails to
approve MACUGEN as the trademark for the Product, or if Pfizer reasonably determines that use of
any of the Trademarks may violate the rights of any third party in the ROW Territory, then the
Parties shall jointly select an alternative trademark for the Product in the applicable country in
the ROW Territory. In either event, Eyetech shall be solely responsible for registering and
maintaining such alternative trademark in the ROW Territory and shall be the owner thereof. Pfizer
shall not register or seek to register any of the Trademarks or any alternative trademark selected
by the Parties in any country of the ROW Territory. Pfizer shall be responsible for the cost in
the ROW Territory of registering and maintaining the Trademarks and any alternative trademark for
the Product.

          9.10 Trademark Infringement. Each Party shall promptly notify the other Party of any
infringement of or challenge to any Trademarks in the ROW Territory, or of any infringement or
alleged infringement of or challenge to any third party trademark in connection with the use of any
Trademarks in the ROW Territory, whether actual or threatened, which comes to the notice of such

47

 

Party. In respect of the defense and infringement of such Trademarks or third party
trademark, as the case may be, in the ROW Territory, as between Pfizer and Eyetech, Pfizer shall
have the first right, at its sole cost and expense, to bring suit and to take action against such
infringer or challenger or to defend any suits or challenges from a third party, in which case
Pfizer shall control the prosecution and/or defense of any such suit or claim, including without
limitation, the choice of counsel, and shall have the exclusive right to settle or dispose of any
such suit or claim. Eyetech shall provide reasonable assistance and co-operation as Pfizer may
reasonably request, at Pfizer’s sole cost and expense. If Pfizer fails to initiate a suit or take
other appropriate action that it has the initial right to initiate or take pursuant to this Section
9.10, within ninety (90) days after becoming aware of the basis for such suit or action, then
Eyetech may, in its discretion, provide Pfizer with written notice of Eyetech’s intent to initiate
a suit or take other appropriate action. If Eyetech provides such notice and Pfizer fails to
initiate a suit or take such appropriate action within thirty (30) days after receipt of such
notice from Eyetech, then Eyetech shall have the right to initiate a suit or take other appropriate
action that it believes is reasonably required to protect the intellectual property rights at
issue. The proceeds of any recovery, court award or settlement of such action shall first be
applied to reimburse the Parties for the costs and expenses of such prosecution and/or defense and
the balance shall be to the Party that initiates such suit or action.

          9.11 Quality Control. Pfizer shall have the right to exercise quality control over
Eyetech’s use of the Pfizer name and logo, and Eyetech shall have the right to exercise quality
control over Pfizer’s use of the Eyetech name and logo and the Trademarks, in each instance to a
degree necessary to maintain the validity of the licensed trademarks and to protect the goodwill
associated therewith. Each Party acknowledges that the quality of the Product sold by the other
Party immediately prior to the Restatement Date (and associated packaging, marketing, and

48

 

advertising materials) is adequate for this purpose. Accordingly, each Party shall, in its
packaging, sale, marketing, advertising, disposition and distribution of the Product adhere to a
level of quality consistent with the level in effect for the packaging, sale, marketing,
advertising, disposition and distribution of the Product by such Party immediately prior to the
Restatement Date.

          9.12 Joint Inventions. The Parties shall jointly own all inventions (a) conceived
jointly by employees, agents and consultants of Eyetech, on the one hand, and employees, agents and
consultants of Pfizer, on the other hand, during the term of this Agreement, or (b) conceived by
consultants engaged jointly by Eyetech and Pfizer during the term of this Agreement in the course
of such consultants’ joint engagement (“Joint Inventions”). Subject to the licenses and
other provisions of this Agreement, each Party shall have the unrestricted right to use and license
Joint Inventions without obtaining consent from, or accounting to, the other Party. For purposes
of determining whether an invention is a Joint Invention, questions of inventorship shall be
resolved in accordance with United States patent laws.

ARTICLE 10

REPRESENTATIONS, WARRANTIES AND COVENANTS 

          10.1 Eyetech Representations and Warranties. Eyetech hereby represents and warrants,
as of the date hereof, to Pfizer as follows:

               (a) Eyetech has the corporate power and authority to execute and deliver this Agreement and to
perform its obligations hereunder, and the execution, delivery and performance of this Agreement by
Eyetech have been duly and validly authorized and approved by proper corporate action on the part
of Eyetech, and Eyetech has taken all other action required by Law, its certificate of
incorporation or by-laws or any agreement to which it is a party or by which it or its assets are
bound required to authorize such execution, delivery and performance. Assuming due authorization,
execution and delivery on the part of Pfizer, this Agreement constitutes a legal, valid

49

 

and binding obligation of Eyetech, enforceable against Eyetech in accordance with its
respective terms.

               (b) The execution and delivery of this Agreement by Eyetech and the performance by Eyetech
contemplated hereunder will not violate any ordinance, Law, decree or government regulation or any
order of any court or other governmental department, authority, agency or instrumentality therein.

               (c) Neither the execution and delivery of this Agreement nor the performance hereof by Eyetech
requires Eyetech to obtain any permits, authorizations or consents from any governmental body or
from any other person, firm or corporation, and such execution, delivery and performance will not
result in the breach of or give rise to any termination of any agreement or contract to which
Eyetech may be a party which relates to the Eyetech Patent Rights, Eyetech Technical Information,
the Compound or the Product.

               (d) There is no action, claim, demand, suit, proceeding, arbitration, grievance, citation,
summons, subpoena, inquiry or investigation of any nature, civil, criminal, regulatory or
otherwise, in law or in equity, pending or, to the best knowledge of Eyetech, threatened against
Eyetech or its Affiliates in connection with the Compound, the Product or any Eyetech Patent Rights
or against or relating to the transactions contemplated by this Agreement

          10.2 Pfizer Representations and Warranties. Pfizer hereby represents and warrants, as
of the date hereof, to Eyetech as follows:

               (a) Pfizer has the corporate power and authority to execute and deliver this Agreement and to
perform its obligations hereunder, and the execution, delivery and performance of this Agreement by
Pfizer have been duly and validly authorized and approved by proper corporate action on the part of
Pfizer, and Pfizer has taken all other action required by Law, its

50

 

certificate of incorporation or by-laws or any agreement to which it is a party or by which it
or its assets are bound required to authorize such execution, delivery and performance. Assuming
due authorization, execution and delivery on the part of Eyetech, this Agreement constitutes a
legal, valid and binding obligation of Pfizer, enforceable against Pfizer in accordance with its
respective terms.

               (b) The execution and delivery of this Agreement and the performance by Pfizer contemplated
hereunder will not violate any state, federal or other statute or regulation or any order of any
court or other governmental department, authority, agency or instrumentality therein.

               (c) There is no action, claim, demand, suit, proceeding, arbitration, grievance, citation,
summons, subpoena, inquiry or investigation of any nature, civil, criminal, regulatory or
otherwise, in law or in equity, pending or relating to or, to the knowledge of Pfizer, threatened
against Pfizer in connection with or relating to the transactions contemplated by this Agreement,
and assuming the accuracy of the representations and warranties of Eyetech contained herein, Pfizer
is unaware and has no reason to be aware of any basis for the foregoing.

               (d) Neither the execution and delivery of this Agreement nor the performance hereof by Pfizer
requires Pfizer to obtain any permits, authorizations or consents from any governmental body or
from any other person, firm or corporation and such execution, delivery and performance will not
result in the breach of or give rise to any termination of any agreement or contract to which
Pfizer may be a party, except that which would not reasonably be expected to adversely affect the
ability of Pfizer to perform its obligations under this Agreement.

          10.3 Eyetech Covenants. Eyetech covenants and agrees that, subject to Pfizer’s and
its sublicensees’ performance of their obligations under this Agreement (including such obligations
relating to third party royalties), Eyetech shall use commercially reasonable efforts to maintain
the

51

 

Isis License, Gilead License and Nektar License in good standing and not to take any actions
(or omit or fail to take any actions) which would result in a breach of any of such license
agreements. Eyetech agrees that it shall not amend, modify or supplement any of the Isis License,
Gilead License or Nektar License in any manner that would adversely affect Pfizer’s rights under
this Agreement without the consent of Pfizer. In addition, Eyetech shall not sell, assign, convey,
pledge, hypothecate or otherwise transfer any of the Isis License, Gilead License or Nektar License
or Eyetech’s rights or obligations thereunder, or otherwise make any commitments or offers in a
manner that conflicts with Pfizer’s rights hereunder without the consent of Pfizer. Eyetech shall
immediately notify Pfizer upon receipt by Eyetech or its Affiliates of any notice from Gilead, Isis
or Nektar of such party’s intent to terminate Eyetech’s rights, exercise its respective rights or
remedies thereunder, or otherwise take any action that may adversely affect Pfizer’s rights under
this Agreement.

          10.4 No Consequential or Punitive Damages. NEITHER PARTY HERETO WILL BE LIABLE FOR
INDIRECT, INCIDENTAL, CONSEQUENTIAL, SPECIAL, EXEMPLARY OR PUNITIVE DAMAGES ARISING FROM OR
RELATING TO ANY BREACH OF THIS AGREEMENT, OR FOR LOST PROFITS ARISING FROM OR RELATING TO ANY
BREACH OF THIS AGREEMENT, REGARDLESS OF ANY NOTICE OF SUCH DAMAGES. NOTHING IN THIS SECTION 10.4
IS INTENDED TO LIMIT OR RESTRICT THE INDEMNIFICATION RIGHTS OR OBLIGATIONS OF EITHER PARTY UNDER
THIS AGREEMENT WITH RESPECT TO THIRD PARTY CLAIMS.

52

 

ARTICLE 11

INDEMNIFICATION

          11.1 General Indemnification in Favor of Pfizer.

               (a) Eyetech shall indemnify, defend and hold Pfizer Parties harmless from and against any and
all Losses incurred, suffered or sustained by Pfizer Parties or to which Pfizer Parties become
subject, arising out of or resulting from:

                    (i) any misrepresentation or breach of any representation, warranty, covenant or agreement
made by Eyetech in this Agreement; or

                    (ii) any third party claims, actions, suits, proceedings, liabilities or obligations
(“Third Party Claims”) arising out of or resulting from:

                         (aa) any misrepresentation or breach of any representation, warranty, covenant
or agreement made by Eyetech in this Agreement; or

                         (bb) the advertising, promotion, distribution, manufacture, use, sale or
importation of the Product by or on behalf of Eyetech or any of its Affiliates or
licensees (except Pfizer), including without limitation all Third Party Claims
involving death or bodily injury caused or allegedly caused by such use or sale of
the Product; or

                         (cc) the gross negligence, recklessness or willful misconduct of Eyetech
Parties in connection with Eyetech’s performance of this Agreement.

For purposes of this Article 11, “Pfizer Parties” means Pfizer and its Affiliates and their
respective agents, directors, officers and employees.

53

 

               (b) None of the indemnities in Section 11.1(a) shall apply to the extent that any Loss is the
result of any breach of this Agreement by Pfizer or of any gross negligence, recklessness or
willful misconduct of Pfizer Parties.

          11.2 General Indemnification in Favor of Eyetech.

               (a) Pfizer shall indemnify, defend and hold Eyetech Parties harmless from and against any and
all Losses incurred, suffered or sustained by Eyetech Parties or to which Eyetech Parties become
subject, arising out of or resulting from:

                    (i) any misrepresentation or breach of any representation, warranty, covenant or agreement
made by Pfizer in this Agreement; or

                    (ii) any Third Party Claims arising out of or resulting from:

                         (aa) any misrepresentation or breach of any representation, warranty, covenant
or agreement made by Pfizer in this Agreement; or

                         (bb) the advertising, promotion, distribution, manufacture, use, sale or
importation of the Product by or on behalf of Pfizer or any of its Affiliates or
licensees (except Eyetech), including without limitation all Third Party Claims
involving death or bodily injury caused or allegedly caused by such use or sale of
the Product; or

                         (cc) the gross negligence, recklessness or willful misconduct of Pfizer Parties
in connection with Pfizer’s performance of this Agreement.

For purposes of this Article 11, “Eyetech Parties” means Eyetech and its Affiliates and
their respective agents, directors, officers and employees.

54

 

               (b) None of the indemnities in Section 11.2(a) shall apply to the extent that any Loss is the
result of any breach of this Agreement by Eyetech or of any gross negligence, recklessness or
willful misconduct of Eyetech Parties.

ARTICLE 12

TERM

          12.1 This Agreement shall be effective as of the date first set forth above and shall remain
in effect until terminated pursuant to Article 13.

ARTICLE 13

TERMINATION

          13.1 Termination for Convenience. Pfizer shall have the right to terminate this
Agreement at any time for any reason in its sole discretion upon written notice to Eyetech, such
termination to be effective sixty (60) days after the date of such notice.

          13.2 Termination for Breach. If either Pfizer or Eyetech materially breaches or
materially defaults in the performance or observance of any of the provisions of this Agreement,
such breach or default has a material adverse effect on the benefits reasonably anticipated by the
non-breaching Party, and such breach or default is not cured within ninety (90) days after the
giving of notice by the other Party specifying such breach or default, then the other Party shall
have the right to terminate this Agreement forthwith, such termination to be effective upon the
expiration of such ninety (90)-day notice period. For the purpose of this Section 13.2, a material
breach or material default in the performance of any of the provisions of this Agreement shall
include a material inaccuracy in any warranty or representation contained herein.

          13.3 Effects of Termination. Upon any termination of this Agreement:

               (a) the licenses set forth in Sections 3.1 and 9.8 shall terminate;

               (b) the rights and licenses set forth in Sections 3.2 and 9.7 shall survive;

55

 

               (c) Eyetech’s right to receive all third party royalty payments due and owing under Article 5
hereof as of the effective date of such termination shall survive;

               (d) each Party’s right to recover against the other Party for any breaches of any
representations, warranties, covenants and agreements of such other Party under this Agreement as
of the effective date of such termination shall survive;

               (e) the provisions of Sections 7.3, 7.4, and this Section 13.3, and Articles 8, 11 and 14,
shall survive;

               (f) Pfizer shall promptly and in no event later than sixty (60) days after termination (i)
transfer to Eyetech ownership of all governmental or regulatory filings and approvals relating to
Product (including, without limitation, any marketing approvals), (ii) deliver to Eyetech all
pre-clinical and clinical data and information in Pfizer’s possession or control relating to the
Product, (iii) deliver to Eyetech copies of all reports, records, regulatory correspondence and
other materials in Pfizer’s possession or control relating to the pre-clinical and clinical
development, regulatory approval, manufacture, distribution and sales of Product, including without
limitation all information contained in the centralized global safety database established and
maintained by Pfizer, and (iv) deliver to Eyetech all data and information relating to process
conditions, in-process controls, analytical methodology and formulation, in each case as developed
by Pfizer and relating to the manufacturing of Product, solely for use in connection with the
Product;

               (g) if requested by Eyetech, assign to Eyetech, subject to any required third party consents,
any agreement that Pfizer has with a Bulk Drug Substance Supplier(s), Fill and Finish Services
Supplier(s), or supplier of any Product Components, with respect to the manufacture of the Product.
Pfizer and Eyetech will each use commercially reasonable efforts (but

56

 

will not be required to make any payments or commence litigation) to obtain any such third
party consent(s) necessary for such requested assignment(s). If Eyetech requests that Pfizer
obtain any required third party consent and the third party from whom such consent is required
refuses to grant the consent or makes any such consent conditional upon payment of additional fees
or upon the assumption of additional obligations or liabilities by Pfizer, then Pfizer shall not be
required to continue to seek such consent but will use commercially reasonable efforts, at no
incremental cost to Pfizer, to provide to Eyetech the benefit of such agreement.

               (h) Pfizer shall permit Eyetech, at Eyetech’s option, to purchase, at Pfizer’s Costs, all or
any part of Pfizer’s unsold inventory of Product Components, work-in-progress Product and finished
Product as of the effective date of termination, provided that, Pfizer shall not be
required to sell to Eyetech inventories of Product Components and work-in-progress Product that
Pfizer needs to satisfy its obligations under Section 13.3(g); and

               (i) unless this Agreement expressly provides that termination shall be the sole and exclusive
remedy for a particular breach hereof, either Party’s right to commence an action, suit or other
proceeding claiming breach of this Agreement by the other Party shall survive termination.

          Upon any termination of this Agreement, each Party shall promptly return to the other Party or
destroy all written Confidential Information, and all copies thereof, of such other Party.

ARTICLE 14

DISPUTE RESOLUTION

          14.1 Arbitration. Any dispute relating to any amounts payable by one Party to the
other pursuant to Section 5, third party royalties payable by Pfizer on sales of Product in the ROW
Territory, or any audit conducted pursuant to Section 7.4 shall be resolved through binding
arbitration as follows:

57

 

               (a) A Party may submit such dispute to arbitration by notifying the other Party, in writing,
of such dispute. Within thirty (30) days after receipt of such notice, the Parties shall designate
in writing a single arbitrator to resolve the dispute; provided, however, that if
the Parties cannot agree on an arbitrator within such 30-day period, the arbitrator shall be
selected by the New York, New York office of the American Arbitration Association (the
“AAA”). The arbitrator shall be a lawyer knowledgeable and experienced in the law
concerning the subject matter of the dispute, and shall not be an Affiliate, employee, consultant,
officer, director or stockholder of any Party.

               (b) Within thirty (30) days after the designation of the arbitrator, the arbitrator and the
Parties shall meet, at which time the Parties shall be required to set forth in writing all
disputed issues and a proposed ruling on the merits of each such issue.

               (c) The arbitrator shall set a date for a hearing, which shall be no later than thirty (30)
days after the submission of written proposals pursuant to Section 14.1(b), to discuss each of the
issues identified by the Parties. The Parties shall have the right to be represented by counsel.
Except as provided herein, the arbitration shall be governed by the Commercial Arbitration Rules of
the AAA; provided, however, that the Federal Rules of Evidence shall apply with
regard to the admissibility of evidence.

               (d) The arbitrator shall use his or her best efforts to rule on each disputed issue within
thirty (30) days after the completion of the hearings described in Section 14.1(c). The
determination of the arbitrator as to the resolution of any dispute shall be binding and conclusive
upon all Parties. All rulings of the arbitrator shall be in writing and shall be delivered to the
Parties.

58

 

               (e) The (i) attorneys’ fees of the Parties in any arbitration, (ii) fees of the arbitrator and
(iii) costs and expenses of the arbitration shall be borne by the Parties as determined by the
arbitrator.

               (f) Any arbitration pursuant to this Section 14.1 shall be conducted in New York, New York.
Any arbitration award may be entered in and enforced by a court in accordance with Section 15.4.

          14.2 No Limitation. Nothing in Section 14.1 shall be construed as limiting in any way
the right of a Party to seek a temporary restraining order or preliminary injunction with respect
to any actual or threatened breach of this Agreement from, or to bring an action in aid of
arbitration in, a court in accordance with Section 15.4. Should any Party seek a temporary
restraining order or preliminary injunction, then for purposes of determining whether to grant such
temporary restraining order or preliminary injunction, the dispute underlying the request for such
temporary restraining order or preliminary injunction may be heard by a court in accordance with
Section 15.4.

ARTICLE 15

MISCELLANEOUS

          15.1 Force Majeure. No Party shall be liable for failure of or delay in performing
obligations set forth in this Agreement, and no Party shall be deemed in breach of its obligations,
if such failure or delay is due to natural disasters or any causes reasonably beyond the control of
such Party.

          15.2 Assignment. Neither this Agreement nor any rights or obligations hereunder may
be assigned or otherwise transferred by either Party without the written consent of the other
Party; provided, however, either Party may, without such consent, assign this
Agreement, in whole or in part: (i) to any of its respective Affiliates; provided
that such Party shall remain jointly and

59

 

severally liable with such Affiliate in respect of all obligations so assigned and such
Affiliate has acknowledged and confirmed in writing that effective as of such assignment or other
transfer, such Affiliate shall be bound by this Agreement as if it were a Party to it as and to the
identical extent applicable to the transferor; (ii) any successor in interest by way of merger,
acquisition or sale of all or substantially all of its assets relating to the business to which the
Product relates, provided that such successor agrees in writing to be bound by the
terms of this Agreement as if it were the assigning Party.

          15.3 Governing Law. This Agreement shall be governed by the laws of the State of New
York without regard to its conflict of laws provisions.

          15.4 Jurisdiction. Except with respect to disputes arising out of audits conducted
pursuant to Section 7.4 or with respect to payment disputes, which shall be resolved through
binding arbitration in accordance with Article 14, each Party (a) irrevocably submits to the
exclusive jurisdiction in the United States District Court for the Southern District of New York
and any State courts sitting in New York, New York (collectively, the “Courts”), for
purposes of any action, suit or other proceeding arising out of this Agreement, and (b) agrees not
to raise any objection at any time to the laying or maintaining of the venue of any such action,
suit or proceeding in any of the Courts, irrevocably waives any claim that such action, suit or
other proceeding has been brought in an inconvenient forum and further irrevocably waives the right
to object, with respect to such action, suit or other proceeding, that such Court does not have any
jurisdiction over such Party.

          15.5 Notices. All notices, instructions and other communications hereunder or in
connection herewith shall be in writing, shall be sent to the address below and shall be: (a)
delivered personally; (b) sent by registered or certified mail, return receipt requested, postage

60

 

prepaid; (c) sent via a reputable nationwide overnight courier service; or (d) sent by
facsimile transmission. Any such notice, instruction or communication shall be deemed to have been
delivered upon receipt if delivered by hand, three (3) Business Days after it is sent by registered
or certified mail, return receipt requested, postage prepaid, one (1) Business Day after it is sent
via a reputable nationwide overnight courier service, or when transmitted with electronic
confirmation of receipt, if transmitted by facsimile (if such transmission is on a Business Day;
otherwise, on the next Business Day following such transmission). Notices shall be addressed as
follows:

	 	 	 
	If to Pfizer:

	 	If to Eyetech:
	 
	 	 
	PFIZER INC.

	 	(OSI) EYETECH, INC.
	235 East 42nd Street

	 	140 E. Hanover Avenue
	New York, New York 10017-5755

	 	Cedar Knolls, New Jersey 07927
	 
	 	 
	Fax: **

	 	Fax: **
	 
	 	 
	Attention: President, Worldwide

	 	Attention: President
	Pharmaceutical Operations
	 	 
	 
	 	 
	with a copy to:

	 	with a copy to:
	 
	 	 
	PFIZER INC.

	 	WILMER CUTLER PICKERING
	235 East 42nd Street

	 	HALE AND DORR LLP
	New York, New York 10017-5703

	 	60 State Street
	Attn.: Senior Vice President and Associate

	 	Boston, Massachusetts 02109
	General Counsel

	 	Attn.: Steven D. Barrett, Esq.
	 
	 	 
	Fax: **

	 	Fax: **

Either Party may change its address by giving notice to the other Party in the manner provided
above.

          15.6 Entire Agreements; Amendments. This Agreement and the other Transaction
Agreements collectively set forth the complete understanding of the Parties with respect to the
subject matter hereof and supersede all prior understandings and writings relating to such subject

 

			
	**	 	This portion has been redacted pursuant to a
confidential treatment request.

61

 

matter, including, without limitation, the Prior Agreements. None of the terms of this
Agreement shall be amended, supplemented or modified except in writing signed by the Parties
hereto. If any applicable court of competent jurisdiction determines this Agreement to be
executory in nature, such agreement shall otherwise be deemed to be, for purposes of Section 365
(n) of the Bankruptcy Code, licenses of rights to “intellectual property” as defined under Section
101 of the Bankruptcy Code.

          15.7 Severability. If and solely to the extent that any provision of this Agreement
shall be invalid or unenforceable, or shall render this entire Agreement to be unenforceable or
invalid, such offending provision shall be of no effect and shall not effect the validity of the
remainder of this Agreement or any of its provisions; provided, however, the
Parties shall use their respective reasonable efforts to renegotiate the offending provisions to
best accomplish the original intentions of the Parties.

          15.8 Waivers. Any term or condition of this Agreement may be waived at any time by
the Party that is entitled to the benefit thereof, but no such waiver shall be effective unless set
forth in a written instrument duly executed by or on behalf of the Party or Parties waiving such
term or condition. Neither the waiver by any Party of any term or condition of this Agreement nor
the failure on the part of any Party, on one or more instances, to enforce any of the provisions of
this Agreement or to exercise any right or privilege, shall be deemed or construed to be a waiver
of such term or condition for any similar instance in the future or of any subsequent breach
hereof. All rights, remedies, undertakings, obligations and agreements contained in this Agreement
shall be cumulative and none of them shall be a limitation of any other remedy, right, undertaking,
obligation or agreement.

62

 

          15.9 Binding Effect. This Agreement shall be binding upon and inure to the benefit of
the Parties hereto and their respective permitted successors and assigns.

          15.10 Further Assurances. Following the date hereof, Eyetech and Pfizer shall and, to
the extent this Agreement expressly imposes obligations on its Affiliates, each Party shall cause
each of its respective Affiliates to, from time to time, execute and deliver such additional
instruments, documents, conveyances or assurances and take such other actions as shall be necessary
or otherwise reasonably requested by Pfizer or Eyetech, to confirm and assure the rights and
obligations provided for in this Agreement, and render effective the consummation of the
transactions contemplated thereby.

          15.11 Third Party Beneficiaries. None of the provisions of this Agreement shall be
for the benefit of or enforceable by any third party including any creditor of either Party. No
third party shall obtain any right under any provision of this Agreement or shall by reasons of any
such provision make any claim in respect of any debt, liability or obligation (or otherwise)
against either Party hereto.

          15.12 Performance by Affiliates. To the extent that this Agreement imposes
obligations on Affiliates of a Party, such Party agrees to cause its Affiliates to perform such
obligations.

          15.13 Counterparts. This Agreement may be executed in any two or more counterparts,
each of which, when executed, shall be deemed to be an original and all of which together shall
constitute one and the same document.

          15.14 Headings. Headings in this Agreement are included herein to ease of reference
only and shall have no legal effect. References to Sections, Schedules and Exhibits are to
Sections, Schedules and Exhibits of this Agreement unless otherwise specified.

63

 

          15.15 Offset. All amounts due and payable from Pfizer to Eyetech pursuant to this
Agreement are subject to offset in respect of the amount of any liabilities of Eyetech paid by
Pfizer to Gilead pursuant to Section 3 of the Stand-By License Agreement between Pfizer and Gilead
dated December 13, 2002.

[Remainder of Page Intentionally Left Blank]

64

 

     IN WITNESS WHEREOF, the Parties hereto have caused this Amended and Restated License Agreement
to be executed as of the Restatement Date by their duly authorized officers.

	 	 	 	 	 	 	 	 	 	 	 
	PFIZER INC.	 	 	 	(OSI) EYETECH, INC.	 	 
	 
	 	 	 	 	 	 	 	 	 	 
	By:

	 	/s/  Susan
Silbermann	 	 	 	By:	 	/s/  Paul G.
Chaney	 	 
	 

	 	 

	 	 	 	 	 	 

	 	 
	 
	 	 	 	 	 	 	 	 	 	 
	Name:

	 	Susan Silbermann	 	 	 	Name:
	 	Paul G. Chaney	 	 
	 

	 	 	 	 	 	 	 	 	 	 
	 
	 	 	 	 	 	 	 	 	 	 
	Title:

	 	S.V.P. WW Commercial
Development	 	 	 	Title:
	 	President	 	 
	 

	 	 	 	 	 	 	 	 	 	 

65

 

SCHEDULES TO AMENDED AND RESTATED LICENSE AGREEMENT

BETWEEN (OSI) EYETECH, INC. AND PFIZER INC.

 

 

SCHEDULE 1.12

COMPOUND

**

 

			
	**	 	This portion has been redacted pursuant to a
confidential treatment request.

S-1

 

SCHEDULE 1.21

EYETECH PATENT RIGHTS

	 	 	 	 	 	 	 	 	 	 	 	 	 
	 	 	Application	 	 	 	 	 	Publication	 	Patent	 	 
	Country	 	Number	 	Filing Date	 	Status	 	Number	 	Number	 	Issue Date
	**
	 	**	 	**	 	**	 	**	 	**	 	**

 

			
	**	 	This portion has been redacted pursuant to a
confidential treatment request.

S-2

 

SCHEDULE 4.2

ONGOING CLINICAL TRIALS

**

 

			
	**	 	This portion has been redacted pursuant to a
confidential treatment request.

S-3

 

SCHEDULE 4.4(c)

ONGOING MARKET RESEARCH ACTIVITIES

**

 

			
	**	 	This portion has been redacted pursuant to a
confidential treatment request.

S-4

 

SCHEDULE 4.4(e)

US TERRITORY AGREEMENTS

Joint Agreements

	 	•	 	Amended and Restated Administrative and Technical Services Agreement by and among The
Lash Group, Inc., Pfizer Inc. and (OSI) Eyetech, Inc. dated March 1, 2006, as amended by
Amendment No. 1 to Amended and Restated Administrative and Technical Services Agreement,
dated as of March 1, 2007.
	 
	 	•	 	Professional Advertising Agency Services Agreement, dated as of January 1, 2004, by and
among Pfizer Inc., Eyetech Pharmaceuticals, Inc., and Medicus New York.
	 
	 	•	 	Public Relations and Communications Services Agreement for MACUGEN®, dated as of January
1, 2006, by and among Pfizer Inc., OSI Pharmaceuticals, Inc. and Daniel J. Edelman, Inc.

Pfizer Agreements

	 	•	 	Professional Services Agreement, dated as of March 15, 2005, by and between CommGenix,
LLC and Pfizer Inc.

S-5

 

SCHEDULE 4.9(b)

MANUFACTURING AND SUPPLY AGREEMENTS

	 	•	 	Manufacturing and Supply Agreement dated as of November 11, 2003, by and between Degussa
Canada Inc. (as successor in interest to Raylo Chemicals Inc.) and Eyetech Pharmaceuticals,
Inc.
	 
	 	•	 	Supply Agreement dated as of October 22, 2004, by and between Eyetech Pharmaceuticals,
Inc. and Sigma-Aldrich, Inc. (formerly Proligo, LLC)

S-6

 

SCHEDULE 4.9(c)

CURRENT INVENTORIES AND OTHER COMPONENTS

**

 

			
	**	 	This portion has been redacted pursuant to a
confidential treatment request.

S-7

 

SCHEDULE 4.9(g)

BUDGET FOR PFIZER CAPITAL EQUIPMENT

AND EXPENDITURES FOR RELATED SERVICES

**

 

			
	**	 	This portion has been redacted pursuant to a
confidential treatment request.

S-8

 

EXHIBITS TO AMENDED AND RESTATED LICENSE AGREEMENT

BETWEEN (OSI) EYETECH, INC. AND PFIZER INC.

 

 

EXHIBIT 1.8

BILL OF SALE

**

 

			
	**	 	This portion has been redacted pursuant to a
confidential treatment request.

E-1

 

EXHIBIT 1.65

TRADEMARKS

[Macugen
Logo]

E-2

 

EXHIBIT 5.2(a)

FORM OF QUARTERLY EXPENSE REPORT

**

 

			
	**	 	This portion has been redacted pursuant to a
confidential treatment request.

E-3EX-10.3

 

[ * ] = Portions of this exhibit have been omitted pursuant to a Confidential Treatment
Request. An unredacted version of this exhibit has been filed separately with the Commission.

FORM OF

ATLAS AIR WORLDWIDE HOLDINGS, INC.

RESTRICTED SHARE AGREEMENT

(PERFORMANCE SHARES)

     THIS RESTRICTED SHARE AGREEMENT (PERFORMANCE SHARES), dated as of February 9, 2007 (the
“Agreement”), is between Atlas Air Worldwide Holdings, Inc. (the “Company”), a Delaware
corporation, and ___ (the “Employee”).

     WHEREAS, the Employee has been granted the following award under the Company’s 2004 Amended
and Restated Long Term Incentive and Share Award Plan (the “Plan”);

     NOW, THEREFORE, in consideration of the premises and mutual covenants contained herein, and
for other good and valuable consideration, the parties hereto agree as follows.

          1. Award of Shares. Pursuant to the provisions of the Plan, the terms of which are
incorporated herein by reference, the Employee is hereby awarded
[•] Restricted Shares (the
“Award”), representing the maximum number of shares that may vest hereunder, subject to the terms
and conditions of the Plan and those set forth herein. The Award is granted on February 9, 2007
(the “Date of Grant”). Capitalized terms used herein and not defined shall have the meanings set
forth in the Plan. In the event of any conflict between this Agreement and the Plan, the Plan shall
control. The term “vest” as used herein with respect to the Award means the lapsing of the
restrictions described herein with respect to such Award.

          2. Vesting of Award; Treatment upon Termination of Service. Unless otherwise
provided by the Committee, all Awards of Restricted Shares under this Agreement, all dividends and
other distributions, whether in cash or otherwise, and other amounts payable with respect to the
Shares shall be subject to the vesting schedule in this Section 2.

          (a) Vesting Generally. Subject to the following provisions of this Section 2 and the
other terms and conditions of this Agreement, this Award shall become vested if, and only if, (1)
the Company achieves certain specified performance levels during the period beginning on January 1,
2007 and ending on December 31, 2009 (the “Performance Period”), and (2) one of the following
conditions is satisfied: (x) the Employee remains continuously employed by the Company or its
subsidiaries from the date hereof until the Determination Date as hereinafter defined, or (y) there
is a Termination of Service of the Employee pursuant to Section 2(c) or 2(d), as further provided
in such Sections, or (z) the conditions of Section 2(e) are satisfied on or before December 31,
2009 and the Employee remains continuously employed by the Company or its Subsidiaries from the
date hereof until the date that such conditions are satisfied.

For the purposes of this Agreement, the term “Determination Date” means the date on which the
Committee determines whether and what level of the Performance Criteria have been achieved. The
Committee shall make such determination no later than April 30, 2010.

          (b) Vesting Upon Satisfaction of Performance Criteria. Notwithstanding anything to
the contrary in this Agreement, shares subject to an Award will vest only upon

 

 

satisfaction of the
achievement of certain ROIC and EBT levels (the “Performance Criteria”), as compared to the ROIC
and EBT of the companies listed in Annex A attached hereto,1 and then in
accordance with Annex B hereto (the “Performance Share Plan Matrix”). Each cell of the
Performance Share Plan Matrix sets forth the percentage of the number of Award shares granted on
the Date of Grant that will vest for each performance level. Any shares underlying an Award that
do not vest due to failure to achieve the Performance Criteria in full or in part shall be
immediately and automatically forfeited to the Company.

               (1) “ROIC” shall mean a fraction where the numerator is the company’s net income
and the
denominator is its total capital, which includes short and long-term debt and capital leases
(including the current portion thereof) plus shareholders equity, in each case calculated in
accordance with generally accepted accounting principles (“GAAP”). ROIC shall be calculated for
the Company and each matrix company by dividing cumulative net income over the Performance Period
by average capital (calculated as the average of capital at December 31, 2006, 2007, 2008 and
2009).

               (2) “EBT” shall mean income before income taxes (or pre-tax income), as adjusted, in
accordance with GAAP. EBT growth for the Company and each matrix company shall be calculated by
averaging the percentage growth in EBT for each of the three years ended December 31 in the
Performance Period. EBT growth for each twelve month period shall be calculated by subtracting EBT
for the twelve months ended December 31 for the current year from EBT for the twelve months ended
December 31 for the prior year and dividing the resulting difference in EBT by the EBT for the
twelve months ended December 31 for the prior year. This calculation will be performed for the
Company and for each matrix company.

               (3) The calculations for ROIC and EBT shall be adjusted for the following non-recurring items
to the extent reflected on the Company’s or the matrix companies’ financial statements: [*]. These
adjustments shall be made on an “After-tax basis” with respect to ROIC and on a pre-tax basis with
respect to EBT. “After-tax basis” shall mean the product of the amount of each non-recurring item
times the difference between one and the effective tax rate as published in the
Company’s and each matrix company’s annual report on Form 10-K for the respective fiscal year
measurement period. The effective tax rate shall mean one (1) minus the ratio of net
income to EBT for each twelve month measurement period.

For the avoidance of doubt, any Award not immediately forfeited under this Agreement will continue
to be forfeitable if the Performance Criteria are not satisfied.

          (c) Death or Disability. In the event of termination of the Employee’s employment
with the Company or its Subsidiaries (a “Termination of Service”) by reason of the Employee’s death
or Disability (as defined below) occurring after the date hereof but before January 1, 2008, the
Employee shall immediately and automatically forfeit the portion of the Award determined by
dividing the number of days from the date of death or Disability until the
end of the Performance Period by the total number of days in the Performance Period and
multiplying the result by the total number of shares subject to the Award. Upon a Termination of
Service by reason of death or Disability occurring on or after January 1, 2008 but before January
1, 2009, the Employee shall immediately and automatically forfeit two-thirds of the Award. Upon a
Termination of

 

			
	1	 	For matrix companies not on a December 31
fiscal year, the average mentioned in Section 2 shall be calculated for the
twelve month period ended December 31.

2

 

Service by reason of death or Disability occurring on or after January 1, 2009 but
before January 1, 2010, the Employee shall immediately and automatically forfeit one-third of the
Award. Upon a Termination of Service by reason of death or Disability on or after January 1, 2010
but before the Determination Date, the Employee shall become entitled to the full amount of the
Award, subject to the fulfillment of the Performance Criteria. For purposes of this Agreement, a
Termination of Service shall be deemed to be by reason of “Disability” if upon such Termination of
Service the Employee qualifies for long term disability benefits under the Company’s Long Term
Disability Plan. Any former Employee or the estate of an Employee will continue to hold the
portion of the Award not forfeited to the Company upon the Termination of Service subject to the
restrictions and all terms and conditions of this Agreement.

          (d) Termination by the Company Not For Cause. In the event of Termination of Service
of the Employee by reason of an involuntary termination by the Company and its Subsidiaries not for
Cause occurring after the date hereof but before January 1, 2008, the Employee shall immediately
and automatically forfeit the portion of the Award determined by dividing the number of days from
the date of the Termination of Service until the end of the Performance Period by the total number
of days in the Performance Period and multiplying the result by the total number of shares subject
to the Award. Upon a Termination of Service of the Employee by reason of an involuntary
termination by the Company and its Subsidiaries not for Cause occurring on or after January 1, 2008
but before January 1, 2009, the Employee shall immediately and automatically forfeit two-thirds of
the Award. Upon a Termination of Service of the Employee by reason of an involuntary termination
by the Company and its Subsidiaries not for Cause occurring on or after January 1, 2009 but before
January 1, 2010, the Employee shall immediately and automatically forfeit one-third of the Award.
Upon a Termination of Service of the Employee by the Company and its Subsidiaries not for Cause
occurring on or after January 1, 2010 but before the Determination Date, the Employee shall become
entitled to the full amount of the Award, subject to the fulfillment of the Performance Criteria.
Any former Employee will continue to hold the portion of the Award not forfeited to the Company
upon the Termination of Service subject to the restrictions and all terms and conditions of this
Agreement. For purposes of this Agreement, “Cause” shall mean (i) the Employee’s refusal or
failure (other than during periods of illness or disability) to perform the Employee’s material
duties and responsibilities to the Company or its Subsidiaries, (ii) the conviction or plea of
guilty or nolo contendere of the Employee in respect of any felony, other than a motor vehicle
offense, (iii) the commission of any act which causes material injury to the reputation, business
or business relationships of the Company or any of its Subsidiaries including, without limitation,
any breach of written policies of the Company with respect to trading in securities, (iv) any other
act of fraud, including, without limitation, misappropriation, theft or embezzlement, or (v) a
violation of any applicable material policy of the Company or any of its Subsidiaries, including,
without limitation, a violation of the laws against workplace discrimination.

          (e) Change in Control. Notwithstanding any provision of this Section 2 to the
contrary, the Award shall become immediately vested in full in connection with and immediately
prior to a Change in Control of the Company (as defined below). For purposes of this
Agreement, “Change in Control of the Company” means and shall be deemed to have occurred if
(i) any Person (within the meaning of the Exchange Act) or any two or more Persons acting in

3

 

concert shall have acquired beneficial ownership (within the meaning of Rule 13d-3 under the
Exchange Act), directly or indirectly, of voting securities of the Company (or other securities
convertible into voting securities of the Company) representing 40% or more of the combined voting
power of all securities of the Company entitled to vote in the election of directors, other than
securities having such power only by reason of the happening of a contingency, or (ii) the Board of
Directors of the Company shall not consist of a majority of Continuing Directors. For purposes of
this Agreement, “Continuing Directors” shall mean the directors of the Company on the date hereof
and each other director, if such other director’s nomination for election to the Board of Directors
of the Company is recommended by a majority of the then Continuing Directors.

          (f) Other Terminations of Service. Except as provided for herein or in the Plan, any
Termination of Service of the Employee occurring before December 31, 2009 (including a Termination
of Service initiated by the employee) and before a Change in Control of the Company, shall result
in an immediate and automatic forfeiture of the full Award.

          3. Other Terms and Conditions. It is understood and agreed that the Award of
Restricted Shares evidenced hereby is subject to the following additional terms and conditions:

          (a) Certificates. Each certificate issued in respect of Restricted Shares awarded
hereunder, if any, shall be deposited with the Company, or its designee, together with, if
requested by the Company, a stock power executed in blank by the Employee, and shall bear a legend
determined by the Company that discloses the restrictions on transferability imposed on such
Restricted Shares by this Agreement (the “Restrictive Legend”). Upon the vesting of Restricted
Shares pursuant to Section 2 hereof and the satisfaction of any withholding tax liability pursuant
to Section 6 hereof, a certificate or certificates evidencing such vested Shares, not bearing the
Restrictive Legend shall be delivered to the Employee or other evidence of vested Shares shall be
provided to the Employee.

          (b) Rights of a Stockholder. Prior to the time a Restricted Share is fully vested
hereunder, the Employee shall have no right to transfer, pledge, hypothecate or otherwise encumber
such Restricted Share. During such period, the Employee shall have all other rights of a
stockholder, including, but not limited to, the right to vote and to receive dividends (subject to
Section 2 hereof) at the time paid on such Restricted Shares.

          (c) No Right to Continued Employment. This Award shall not confer upon the Employee
any right with respect to continuance of employment by the Company nor shall this Award interfere
with the right of the Company to terminate the Employee’s employment at any time.

          4. Transfer of Shares. The Shares delivered hereunder that have vested, or any
interest therein, may be sold, assigned, pledged, hypothecated, encumbered, or transferred or
disposed of in any other manner, in whole or in part, only in compliance with the terms, conditions
and restrictions as set forth in the governing instruments of the Company, applicable
federal and state securities laws or any other applicable laws or regulations and the terms
and

4

 

conditions hereof. Otherwise, the Award shall not be sold, assigned, pledged, hypothecated,
encumbered, or transferred or disposed of in any other manner, in whole or in part.

          5. Expenses of Issuance of Shares. The issuance of stock certificates hereunder shall
be without charge to the Employee. The Company shall pay, and indemnify the Employee from and
against any issuance, stamp or documentary taxes (other than transfer taxes) or charges imposed by
any governmental body, agency or official (other than income taxes) by reason of the issuance of
Shares.

          6. Tax Withholding. No later than the date of vesting of (or the date of an election
by the Employee under Code section 83(b) with respect to) the Awards the Employee shall pay to the
Company an amount sufficient to allow the Company to satisfy its tax withholding obligations. To
this end, the Employee shall either:

	 	(a)	 	pay the Company the amount of tax to be withheld (including
through payroll withholding),
	 
	 	(b)	 	deliver to the Company other shares of stock of the Company
owned by the Employee prior to such date having a fair market value, as
determined by the Committee, not less than the amount of the withholding tax
due, which either have been owned by the Employee for more than six (6) months
or were not acquired, directly or indirectly, from the Company,
	 
	 	(c)	 	make a payment to the Company consisting of a combination of
cash and such shares of stock, or
	 
	 	(d)	 	request that the Company cause to be withheld a number of
vested shares of stock having a then fair market value sufficient to discharge
minimum required federal, state and local tax withholding (but no greater than
such amount).

          7. References. References herein to rights and obligations of the Employee shall
apply, where appropriate, to the Employee’s legal representative or estate without regard to
whether specific reference to such legal representative or estate is contained in a particular
provision of this Agreement.

          8. Notices. Any notice required or permitted to be given under this Agreement shall
be in writing and shall be deemed to have been given when delivered personally or by courier, or
sent by certified or registered mail, postage prepaid, return receipt requested, duly addressed to
the party concerned at the address indicated below or to such changed address as such party may
subsequently by similar process give notice of:

5

 

If to the Company:

Atlas Air Worldwide Holdings, Inc.

2000 Westchester Avenue

Purchase, New York 10577

Attention: General Counsel

If to the Employee:

At the Employee’s most recent address shown on the Company’s
corporate records, or at any other address which the Employee may
specify in a notice delivered to the Company in the manner set forth
herein.

          9. Governing Law. This Agreement shall be governed by and construed in accordance
with the internal laws of the State of New York, without giving effect to principles of conflicts
of laws of any jurisdiction which would cause the application of law, other than the State of New
York, to be applied.

          10. Counterparts. This Agreement may be executed in two counterparts, each of which
shall constitute one and the same instrument.

          11. Acknowledgements. The Employee hereby acknowledges (i) that he or she has been
advised to confer promptly with a professional tax advisor to consider whether he or she should
make a so-called “83(b) election” with respect to the Award and (ii) that he or she has received of
a copy of the Plan as in effect on the date hereof.

[SIGNATURE PAGE FOLLOWS AS A SEPARATE PAGE]

6

 

     IN WITNESS WHEREOF, the undersigned have executed this Restricted Share Agreement (Performance
Shares) as of the date first above written.

	 	 	 	 	 	 	 
	 	 	ATLAS AIR WORLDWIDE HOLDINGS, INC.

	 	 
	 

	 	By:	 	 	 	 
	 

	 	 	 	 	 	 
	 

	 	 	 	Name:	 	 
	 

	 	 	 	Title:

	 	 
	 	 	 	 	 
	 	 	Employee	 	 

 

 

Annex A

Matrix Companies

	 
	[*]

	[*]

	[*]

	[*]

	[*]

	[*]

	[*]

	[*]

	[*]

	[*]

	[*]

	[*]

	[*]

	[*]

	[*]

	[*]

	[*]

	[*]

	[*]

	[*]

	[*]

	[*]

If ROIC or EBT information is unavailable for one of the companies listed above, then such company
shall be omitted from the list of matrix companies and from any and all calculations under this
Agreement.

 

 

Annex B

Performance Share Plan Matrix

Performance Relative to Matrix Companies: ROIC

	 	 	 	 	 	 	 	 	 	 	 
	Performance	 	 	 	 	 	 	 	 	 	 
	Relative to	 	 	 	 	 	 	 	 	 	 
	Matrix	 	 	 	 	 	 	 	 	 	 
	Companies:	 	 	 	 	 	 	 	 	 	 
	EBT Growth	 	[*]	 	[*]	 	[*]	 	[*]	 	[*]
	[*]

	 	[*]
	 	[*]
	 	[*]
	 	[*]
	 	[*]
	[*]

	 	[*]
	 	[*]
	 	[*]
	 	[*]
	 	[*]
	[*]

	 	[*]
	 	[*]
	 	[*]
	 	[*]
	 	[*]
	[*]

	 	[*]
	 	[*]
	 	[*]
	 	[*]
	 	[*]
	[*]

	 	[*]
	 	[*]
	 	[*]
	 	[*]
	 	[*]

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00122-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00122-of-00352.parquet"}]]